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General introduction
Complex Regional Pain Syndrome (CRPS) is characterized by a continuing regional pain 
that is disproportionate in time or degree to the usual course of any known trauma or le-
sion. The pain is regional, not in a specific nerve territory or dermatome, and usually has 
a distal predominance. CRPS is characterized by a variable progression over time (IASP 
Committee for Classification of Chronic Pain 2012 (http://www.iasp-pain.org/Education/
Content.aspx?ItemNumber=1698)).
The first scientific paper on CRPS was published more than 100 years ago by Sudeck1 
and his name was linked to the syndrome for many years (Sudeck’s dystrophy). The syn-
drome has also been referred to by many other terms, but was most commonly called 
‘reflex sympathetic dystrophy’ (RSD). Then, based on a consensus meeting of the IASP 
in 1993, the term ‘complex regional pain syndrome’ was agreed upon.2 CRPS was further 
divided into type 1 and type 2, with CRPS 1 corresponding to the general image of RSD 
and CRPS 2 to causalgia.
CRPS is generally characterized by a combination of continuing pain, sensory, va-
somotor, sudomotor and motortrophic symptoms. In addition, spontaneous and/or 
evoked pain and sensory disturbances, such as allodynia and hyperesthesia, changes in 
skin color and skin temperature, edema, hyper/hypohidrosis, and limited active range of 
motion are often present. Furthermore, tremor, involuntary movement, muscle spasm, 
skin, muscle and bone atrophy, and changes in hair and nail growth are reported by 
patients with this syndrome.3 For the clinical diagnosis of CRPS, it is currently recom-
mended to use the Budapest criteria.4 In 2012, these latter criteria were accepted and 
codified by the IASP Committee for Classification of Chronic Pain (http://www.iasp-pain.
org/Education/Content.aspx?ItemNumber = 1698).
The estimated overall incidence rate of CRPS varies from 5.46 to 26.2 per 100,000 
person years.5,6 Females are affected at least three times more often than males. The 
highest incidence occurs in females in the age group of 61-70 years. The upper extremity 
is affected more frequently than the lower extremity, and a fracture is the most common 
precipitating event.6 Severe CRPS outcome is relatively rare, but incomplete resolution 
of all signs and symptoms is common and (based on self-reports) only about one-third 
of the patients reach full recovery.7 CRPS outcome is worse in patients with the involve-
ment of the upper extremity, a precipitating injury other than a fracture, and in case of 
‘cold’ CRPS.
Although the pathophysiology of CRPS is complex and not completely understood, 
different underlying mechanisms seem to contribute to the pathophysiology. Referring 
to its earlier name (RSD), sympathetic dysfunction is one such mechanism.8,9 Pathology 
of the sensory somatic nervous system is demonstrated by both peripheral mecha-
nisms, e.g. minimal distal nerve injury affecting nociceptive small fibers10, and central 
mechanisms, such as cortical reorganization.11 Hypoxia has been shown in CRPS12 and 
might be caused by endothelial dysfunction.13 Furthermore, inflammation seems to be 
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an important mechanism. Potential connections between these separate mechanisms 
have also been described.14
There is considerable evidence for the involvement of inflammation in CRPS; more-
over, inflammation seems to play a pivotal role in the pathophysiology of CRPS. CRPS 
often displays the classic aspects of inflammation, e.g. pain, redness, swelling, warmth 
and functio laesa.3 Inflammation can arise from two sources. Classic inflammatory 
mechanisms can contribute through actions of immune cells (such as lymphocytes 
and mast cells), which secrete pro-inflammatory cytokines after tissue trauma. Mast 
cells are known to be involved in CRPS.15 Neurogenic inflammation may also occur, 
mediated by release of neuropeptides like calcitonin gene-related peptide16 and 
substance-P.17
However, local rather than systemic inflammatory responses appear to be relevant 
in CRPS. Based on the clinical signs and symptoms Sudeck originally proposed the idea 
of inflammation. In 1993, in a scintigraphic study on CRPS, Oyen et al. demonstrated 
vascular permeability for macromolecules, a classical phenomenon of inflammation.18 
Tumor necrosis factor alpha (TNF-α) is a cytokine that promotes an inflammatory 
response. Increased levels of this pro-inflammatory cytokine have been detected in 
fluid from artificially raised skin blisters in the involved extremity in comparison to the 
contralateral site.13,19-21 Also in skin punch biopsies, TNF-α was significantly elevated in 
CRPS compared to patients with osteoarthritis.22 A case series showed that TNF-α was 
only localized in the affected hand of patients with early CRPS using a technetium 99 
m-anti-TNF-α antibody scintigraphy.23 Finally, venous blood of CRPS patients shows 
normal systemic inflammatory parameters (i.e. normal white blood cell count and C-
reactive protein).24
In addition to this convincing role for inflammation, several arguments exist for in-
volvement of the immune system in the pathophysiology of CRPS. CRPS shows a benefi-
cial response to treatment in open-label studies on treatment with immunomodulating 
medication, such as infliximab25 and immunoglobulin.26 Furthermore, similar to many 
other inflammatory diseases, CRPS displays a female predominance6 and associations 
with distinct HLA alleles.27,28
The aim of the work presented in this thesis was to further explore the immunological 
aspects of CRPS in order to gain more insight into the pathophysiology of CRPS and the 
appropriateness of various pharmacotherapeutic interventions.
Pathophysiology
Generally, it is assumed that inflammation is absent in cold CRPS.14 However, some 
patients with cold CRPS have displayed full-blown symptoms of warm CRPS after va-
sodilatation therapy.29 Therefore, it seems that inflammation could be ‘hidden’ behind 
vasomotor disturbances. A study was designed to test this hypothesis.
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Autoimmunity is suggested as one of the pathophysiological mechanisms to under-
lie CRPS. A study was designed to further explore CRPS as a potential autoantibody-
associated autoimmune process.
Pharmacotherapeutic interventions
In clinical practice, patients with CRPS are often grouped based on their signs and 
symptoms, and medication is generally administered depending on these signs and 
symptoms. Woolf and Decosterd advocated a form of pain treatment based on the 
mechanisms involved in the pathogenesis of pain.30 In each patient, the aim should be 
to identify which mechanisms are responsible for the pain and treatment is then specifi-
cally targeted to those mechanisms. Based on this recommendation, it appears that the 
current strategy applied for therapy may not be correct.
Immunomodulating medication reduces the manifestation of inflammation by influ-
encing the mediators of inflammation, such as cytokines and neuropeptides. Assuming 
that inflammation plays an important role, it seems more appropriate to correct the 
baseline inflammatory status to lower disease activity by giving immunomodulating 
medication. The current empirical evidence for the benefit of administering the most 
commonly used immunomodulating medication in CRPS was investigated in a sys-
tematic review. In addition, a double-blind randomized controlled trial was conducted 
with the aim to confirm this statement by administering the tumor necrosis factor-α 
antagonist (i.e. infliximab).
It is unknown whether (apart from the immunomodulating medication) other drugs 
might also counteract the inflammation. Based on empirical findings on the role of mast 
cells in the pathophysiology of inflammation in CRPS15, we investigated the rationale for 
the use of medication targeting mast cell activity.
The results of the studies presented in this thesis may, hopefully, improve the treatment 
and outcome of patients suffering from CRPS.
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AbStRACt
background
In patients with Complex Regional Pain Syndrome (CRPS) the temperature of the affected 
side often differs from that of the contralateral side. In the acute phase, the affected side 
is usually warmer than the contralateral side, the so-called ‘warm’ CRPS. This thermal 
asymmetry can develop into a colder affected side, the so-called ‘cold’ CRPS. In contrast 
to cold CRPS, in warm CRPS inflammation is generally assumed to be present. However, 
there are reports of cold CRPS patients, successfully treated with vasodilatation therapy, 
who subsequently displayed warm CRPS. It seems that inflammation could be ‘hidden’ 
behind vasomotor disturbance. This study was designed to test this hypothesis.
Methods
A retrospective analysis was made of patients in our CRPS database. We defined three 
types of CRPS: cold CRPS, neither cold nor warm (intermediate) CRPS and warm CRPS. 
Of these patients the difference between the level of the pro-inflammatory cytokines 
IL-6 (Δ IL-6) and TNF-α (Δ TNF-α) in the affected extremity and that in the contralateral 
extremity was determined.
Results
The bilateral difference of the level of these cytokines did not differ between patients 
with cold CRPS, intermediate CRPS or those with warm CRPS
Conclusion
Inflammation may be involved in cold CRPS.
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intRoDuCtion
Complex Regional Pain Syndrome (CRPS) is a collection of locally appearing painful 
conditions following a trauma; these symptoms mainly occur distally and exceed in in-
tensity and duration the expected clinical course of the original trauma, often resulting 
in considerable restricted motor function.
Especially in the acute phase, CRPS often displays the classic signs of inflammation1 
and there is evidence that local inflammation plays an important role in the pathophysi-
ology of CRPS.2-5 According to Bruehl, this particularly applies to the acute ‘warm’ phase.6
A transition from a warm/red to a cold/ bluish CRPS presentation is common as CRPS 
moves from the acute to a chronic stage6; however, some patients are cold from the 
onset.1
Although several mechanisms are reported to be responsible for cold CRPS, the 
mechanism behind the sympathetic dysfunction in CRPS remains controversial.5 In-
creased sympathetic outflow (hyperactivity) is one possibility7 and abnormal sensitivity 
of adrenergic receptors for normal sympathetic outflow is another.8
Nociceptive afferent input may be caused by an increase in the number of alpha 1 
adrenoceptors in the affected extremity, increased peripheral alpha adrenergic recep-
tor hypersensitivity, and chemical coupling between the sympathetic and nociceptive 
neurons in the skin of CRPS-affected limbs.9 Also, there might be impaired endothelium-
dependent vasodilation, indicating endothelial dysfunction.10 In addition, the nitric 
oxide/endothelin-1 (NO/ET-1) ratio may be disturbed in the intermediate stage of CRPS, 
resulting in vasoconstriction.11 Whether or not vasoconstriction in CRPS is related to the 
above mechanisms, vasoconstriction might trigger a vicious circle of tissue hypoxia, 
acidosis and increased production of free radicals.
In cold CRPS, inflammation is generally assumed not to be present.5 However, there 
are reports of ‘cold’ CRPS patients, who displayed full-blown symptoms of ‘warm’ CRPS 
after been successfully treated with vasodilatation therapy.12 It seems that inflammation 
can be ‘hidden’ behind vasomotor disturbance.
In pathological situations (like inflammation), circulating cytokines [e.g. tumor ne-
crosis factor (TNF)-α] induce the expression of inducible NO synthase (iNOS) and ET-1 in 
smooth muscle cells; they also downregulate endothelial NO synthase (eNOS) expres-
sion in endothelial cells. Increased NO generated by iNOS can react with superoxide 
anion to produce peroxynitrite, which can cause further endothelial dysfunction.13 This 
imbalance between the NO/ET-1 system is described in cold CRPS.11
These findings led to our hypothesis that, (a subgroup of ) patients with cold CRPS 
might still suffer from inflammation. To test this hypothesis, the difference between the 
level of the pro-inflammatory cytokines IL-6 (Δ IL-6) and TNF-α (Δ TNF-α) in the affected 
extremity and that in the contralateral extremity was determined. The bilateral differ-
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ences were compared between patients with cold CRPS, with neither warm nor cold 
CRPS and those with warm CRPS.
MethoDS
A retrospective analysis was made of data from our CRPS database.
Patients
Sixty-six patients with CRPS in one extremity met the diagnostic criteria of Bruehl et al.14 
All participated in several studies performed between 2001 and 2005. The aim of those 
studies was to investigate the pathophysiology of CRPS and/or the effects of specific 
treatments for CRPS.4 The protocol was approved by the Medical Ethics Committee of 
the Erasmus MC, P.O. 2040 3000 CA Rotterdam (protocol no. 2001/024) on 1 February 
2001.
Measurements
Besides demographic and clinical variables (symptoms and signs), temperature and 
cytokine levels in artificial skin blisters were determined in both the involved and con-
tralateral extremity.
temperature measurement
Skin temperature was measured using an infrared tympanic probe thermometer. 
Measurements were obtained on the dorsal aspect of the hand or foot in a matrix of 
five points; the difference in mean temperature between the involved and contralateral 
extremity was calculated.4
The measurements were performed at a constant room temperature of 23±0.5°C and 
the patients had to acclimatize for at least 15 minutes. Psychological state can affect 
limb temperature. However, the influence of psychological parameters is systemic and 
therefore will not confound our parameter (bilateral difference in temperature).
We defined three types of CRPS: cold CRPS as an asymmetry cut-off between the 
affected and contralateral extremity of ≥ −0.6°C, as recommended by Bruehl et al.15 
Intermediate CRPS was defined as a thermal asymmetry between −0.59°C and < +0.6°C 
and warm CRPS as an asymmetry of ≥ +0.6°C.
Cytokine assays
Levels of the pro-inflammatory cytokines TNF-α and IL-6 were determined in fluid from 
artificially-derived blisters. Blisters were induced using a suction method. A skin suction 
chamber was positioned on the skin of the involved and contralateral extremities. A 
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vacuum of 300 mmHg was applied with an Atmoforte 350A aspirator pump (ATMOS 
Medizintechnik, Lenskirch, Germany). After 15 min, the vacuum was reduced to 250 
mmHg and, after another 15 min, was reduced to 200 mmHg. This negative pressure was 
maintained for 2-2.5 h. The blisters created were punctured, and fluid was pooled from 
each side into a 1.5-ml Eppendorf conical polypropylene tube (Eppendorf AG, Hamburg, 
Germany) and centrifuged for 5 min at 1600 x g.4
Blister fluid samples were diluted in appropriate calibrator diluent assay buffer for 
the direct measurement of cytokines. Cytokine assays were performed following the 
manufacturer’s protocol [PeliKine human ELISA kits for IL-6 (M1906) and TNF-α (M1920); 
CLB, Amsterdam, The Netherlands]. The standard curve ranges and mean calculated 
zero signal ± 3 [standard deviation (SD)] were 0-80 and 0.3 pg/ml for IL-6 and 0-1000 and 
1 pg/ml for TNF-α, respectively. The absorbance per well was measured at 450 nm with 
a Medgenix EASIA reader (BioSource Europe S.A., Nivelles, Belgium). Sample concentra-
tions were calculated using the appropriate standard calibration lines and the Softmax® 
software (Molecular Devices, Sunnyvale, CA, USA) of the reader.4
Because the specific distribution of TNF-α and IL-6 in the general population in suc-
tion blister fluid is unknown, no data on aberrant levels are available. Therefore, for the 
present study, the difference between the affected and the contralateral extremity was 
measured (Δ TNF-α and Δ IL-6). The start of inducing the artificially-derived blisters was 
always at the end of the morning, so the sample time could not affect any possible dif-
ferences in cytokine concentrations during the day.
Statistical analysis
Descriptive statistics were used to determine the frequencies of the demographic, 
clinical and outcome parameters and to describe measures of central tendency and of 
dispersion, dependent on the shape of their distribution. The Kolmogorov-Smirnov test 
was used to estimate whether or not the parameters were normally distributed. The dif-
ference in IL-6 and TNF-α level between the affected and contralateral side is depicted 
in a scatter plot.
To estimate whether the parameters differed statistically significant between the 
three types of CRPS the Kruskal-Wallis (non-normally distributed), One-way analysis of 
variance (normally distributed) and the Pearson Chi-Square (proportional differences) 
tests were used.
Analyses were performed using the IBM SPSS Statistics for Windows, Version 21.0 (IBM 
Corp., Armonk, NY, USA).
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ReSultS
Of the 66 included patients, data on pro-inflammatory cytokines were available for 48 of 
them. Based on the temperature asymmetry and the above mentioned cut-off scores, 19 
(39.6%) of these patients suffered from a cold CRPS, 20 (41.7%) from an intermediate and 
9 (18.7%) from a warm CRPS. Thirty two (66.7%) of the 48 patients were female. Mean 
age was 46.7 (SD 11.15) years; median duration of CRPS was 5.5 [interquartile range (IQR) 
9] months, and median difference in temperature between the affected and contralat-
eral extremity was −2.5°C (IQR 1.33, Range 9). Only gender did not differ between the 
types CRPS (see Table 1). The clinical phenotypes in terms of symptoms and signs are 
depicted in Table 2. Of seven patients data were missing. Only the signs of allodynia and 
hyperesthesia differed significantly between the types of CRPS.
table 1. Patients’ characteristics by type of CRPS
Type of CRPS p
Cold Intermediate Warm
Female gender n (%) 11 (34.4) 14 (43.8) 7 (21.8) .53
Age / years mean (sd) 42.1 (11.58) 48.1 (10.5) 53.2 (8.07) .034
Duration / months median (IQR) 12 (27) 4 (7.5) 2 (3.75) .005
table 2. Symptoms and signs by type of CRPS
Symptoms Signs
Cold Intermediate Warm p Cold Intermediate Warm p
Sensory n (%) n (%) n (%) n (%) n (%) n (%)
Allodynia 10 (66.7) 11 (64.7) 6 (66.7) .99 6 (40.0) 13 (76.5) 3 (33.3) .046
Hyperesthesia 15 (100) 14 (82.4) 8 (88.9) .24 8 (53.3) 1 (5.9) 4 (44.4) .01
Vasomotor
Asymmetry in temperature 15 (100) 17 (100) 9 (100) 1 15 (100) 12 (70.6) 7 (77.8) .08
Asymmetry in color 15 (100) 17 (100) 9 (100) 1 10 (66.7) 15 (88.2) 8 (88.9) .24
Sudomotor
Edema 14 (93.3) 17 (100) 9 (100) .41 13 (86.7) 13 (76.5) 9 (100) .27
Asymmetry in sweating 9 (60.0) 14 (82.4) 5 (55.6) .26 9 (60.0) 5 (29.4) 3 (33.3) .18
Motortrophic
Decreased range of motion 15 (100) 15 (88.2) 8 (88.9) .39 14 (93.3) 15 (88.2) 9 (100) .55
Weakness 11 (73.3) 13 (76.5) 7 (77.8) .97 4 (26.7) 4 (23.5) 5 (55.6) .22
Dystonia 10 (66.7) 9 (52.9) 4 (44.4) .54 4 (26.7) 5 (29.4) 1 (11.1) .57
Change hair/ nail growth 10 (66.7) 10 (58.8) 3 (33.3) .27 7 (46.7) 6 (35.3) 2 (22.2) .48
The use of anti-inflammatory medication [dimethylsulfoxide, N-acetylcysteine, vitamin 
C and nonsteroidal anti-inflammatory drug] at the time of inducing the blisters was also 
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registered. Twelve (63%) of the 19 patients with cold CRPS, 15 (75%) of the patients with 
intermediate CRPS, and 5 (56%) with warm CRPS used one or more of these medication. 
These proportions did not differ statistically significant between the types of CRPS. The 
proportions of the patients using a specific medication also did not differ significantly 
between the types of CRPS (see Table 3).
table 3. Medication use at the time of inducing of the blisters
Type of medication Type of CRPS p
Cold
(n=19)
n (%)
Intermediate
(n=20)
n (%)
Warm
(n=9)
n (%)
Dimethylsulfoxide 9 (47.3) 12 (60) 5 (55.6) .73
N-acetylcysteine 3 (15.7) 3 (15) 1(11.1) .95
Vitamin C 0 (0) 1 (5) 0 (0) .49
Nonsteroidal Anti-Inflammatory Drugs 7 (36.8) 5 (25) 1 (11.1) .35
Immunomodulating medication 0 (0) 0 (0) 0 (0) -
No medication 7 (36.8) 5 (25) 4 (44.4) .54
Note: because some patients used more than one type of medication the percentage of cases does not 
add up to 100.
The distributions of Δ TNF-α and of Δ IL-6 did not statistically significant differ between 
the patients with a cold, an intermediate or a warm CRPS (see Table 4 and Figure 1).
table 4. Median and dispersion of Δ TNF-α and Δ IL-6 by type of CRPS
Δ TNF-α Δ IL-6
Type of CRPS p Type of CRPS p
Cold Intermediate Warm Cold Intermediate Warm
Median (IQR) 8.1 (102.4) 12.3 (28.0) 12.3 (28.0) .99 11.1 (68.0) 44.0 (112.8) 1.6 (63.3) .16
DiSCuSSion
The results of this study show that the three patients groups differing in asymmetrical 
level of temperature do not significantly differ in asymmetric levels of the pro-inflamma-
tory cytokines TNF-α and IL-6. Likewise, post-hoc pairwise comparison between these 
groups did not yield a statistically significant difference between these cytokines either, 
nor comparison of cold versus warm and intermediate as one group (TNF-α, p = .87; IL-6, 
p = .23).
Assuming that the patients with a warm CRPS suffer from inflammation and the 
asymmetric level of the cytokines reflect the presence of inflammation, then our finding 
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is in accordance with the idea that a (subgroup of ) patients with cold CRPS might (still) 
suffer from inflammation.
In clinical practice, patients with CRPS are often grouped (cold vs. warm) based on 
their signs/symptoms, and medication is generally administered dependent on these 
signs and symptoms. Our findings suggest that this may be one of the reasons why 
clinical trials have failed to support the efficacy of many commonly used interventions. 
Because our findings indicate that the treatment should be based on the underlying 
mechanism, i.e., irrespective of the thermal asymmetry, inflammation might still be 
part of the pathophysiology of cold CRPS. Therefore, patients with a cold CRPS and un-
derlying inflammation may benefit more from medication that influences the ongoing 
inflammation rather than merely vasodilatation therapies.16
It is currently not possible to establish the extent to which the individual mecha-
nisms participate in the development of cold CRPS. However, it is possible to determine 
whether or not there is an ongoing inflammatory process. As suggested, a selection of 2 
or 3 representatives from the inflammatory cytokine panel, the Th1/Th2 cytokine panel 
and the chemokine panel would be sufficient to indicate the inflammatory activity of 
the CRPS disease.17 However, obtaining fluid from artificial skin blisters to determine 
cytokine levels is a time-consuming procedure that limits its routine use for diagnostic 
purposes in the outpatient clinic.
 
 
figure 1. Scatterplot of the difference of IL-6 and TNF-α between the affected and the contralateral side 
by type of CRPS
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From a practical point of view we recommend that, irrespective of the amount or 
direction of existing thermal asymmetry, the concept of (ongoing) inflammation in CRPS 
should be taken into account when considering therapy. In patients with cold CRPS, if 
vasodilatation treatment results in an exacerbation of inflammatory signs and symp-
toms then anti-inflammatory therapy should certainly be considered.
The stability of an increase in asymmetric levels of cytokines is unfortunately un-
known. If the stability is low then our measurements could be biased and conclusions 
should be interpreted accordingly. Other points for discussion are the facts that the 
duration and age differed significantly between the types of CRPS. The difference in the 
duration is in accordance with the commonly encountered transition from a warm/red 
to a cold/bluish CRPS presentation as CRPS moves from the acute to a chronic stage. 
Although we see no plausible reason for a confounding effect of this difference between 
the types of CRPS, theoretically it cannot be excluded. The same applies to the difference 
in age between the types of CRPS.
Patients were treated according to the Dutch guidelines for CRPS.18 For nociceptive 
pain treatment, the WHO analgesic ladder is advised and for inflammatory symptoms 
free-radical scavengers. Immunomodulating medications are not advised. (Some of ) 
the prescribed medication might influence the absolute cytokines levels, it however 
is unlikely that it might influence the bilateral differences in cytokine levels. Moreover, 
the proportion of patients using this medication(s) did not differ between the types of 
CRPS. We therefore are confident that medication use was not a confounder affecting 
the external validity of our results.
We recommend further research into the pathophysiological mechanism of inflam-
mation in CRPS. If the levels of pro-inflammatory cytokines are measured, this should be 
done repeatedly.
In conclusion, inflammation might (still) play a role in (a subgroup of ) patients with 
cold CRPS.
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AbStRACt
Autoimmunity has been suggested as one of the pathophysiologic mechanisms that 
may underlie complex regional pain syndrome (CRPS).
Screening for antinuclear antibodies (ANA) is one of the diagnostic tests, which is 
usually performed if a person is suspected to have a systemic autoimmune disease. 
Anti-neuronal antibodies are auto-antibodies directed against antigens in the central 
and/or peripheral nervous system. The aim of this study was to compare the prevalence 
of these antibodies in CRPS patients with the normal values of those antibodies in the 
healthy population.
Twenty seven (33%) of the 82 CRPS patients of whom serum was available, showed a 
positive ANA test. This prevalence is significantly higher than in the general population.
Six patients (7.3%) showed a positive result for typical anti-neuronal antibodies. This 
proportion, however, does not deviate from that in the general population.
Our findings suggest that auto-antibodies may be associated with the pathophysiol-
ogy of CRPS, at least in a subset of patients. Further research is needed into defining this 
subset and into the role of auto-antibodies in the pathogenesis of CRPS.
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intRoDuCtion
Complex Regional Pain Syndrome (CRPS) is a collection of locally appearing painful 
conditions following trauma which chiefly occur distally and exceed in intensity and 
duration the expected clinical course of the original trauma.
The pathophysiology is complex and still not completely understood. It is reasonable 
to assume that different mechanisms, e.g. inflammation, hypoxia, central sensitisation 
and neuroplasticity, are involved in a complex network of interactions, resulting in a 
broad range of signs and symptoms.1
The involvement of the immune system in the pathophysiology of CRPS is appreciated 
for several reasons. First, CRPS shows several clinical characteristics of an inflammatory 
disease, including pain, redness, swelling and warmth.2 Additionally, levels of pro-inflam-
matory cytokines are elevated in blister fluid from CRPS affected limbs.3,4 CRPS shows a 
beneficial response to treatment with inhibitors of inflammation, such as corticosteroids.5
Complementary is the fact that, similar to many other chronic inflammatory diseases, 
CRPS displays a female predominance6 and associations with distinct HLA alleles.7-9 The 
incidence of CRPS is higher in patients with chronic inflammatory disorders, such as 
asthma10 and multiple sclerosis.11
Autoimmunity has been suggested as one of the underlying mechanisms in the 
pathophysiology of CRPS. There are several arguments that point in this direction. First, 
IgA-antibodies to Campylobacter were present in CRPS patients with short disease dura-
tion12 and an increased seroprevalence of Parvovirus B19 in CRPS patients compared to 
controls has been reported.13,14 Both infectious agents have previously been implicated 
in the induction of autoimmune diseases.
Second, immunohistochemistry has revealed the presence of auto-antibodies 
against nervous system structures in at least a part of the CRPS-patients, included in a 
study by Blaes et al.15 Another study showed that about 30-40% of CRPS patients have 
surface-binding auto-antibodies against an inducible autonomic nervous system auto-
antigen.16 Third, a subgroup of CRPS patients, i.e. those who developed CRPS with only a 
minimal preceding trauma, showed a much stronger immune response against nervous 
tissue compared to the whole group.12 Fourth, animal studies have demonstrated that 
the transfer of IgG antibodies from CRPS patients to mice causes abnormal behaviour 
and motor function in these mice.17 And finally, treatment with intravenous immuno-
globulin can reduce pain in refractory CRPS.18
These results suggest that CRPS is associated with autoimmunity, including an auto-
antibody-mediated immune process, at least in a part of the patients. Interestingly, CRPS 
is even considered as prototype of a novel kind of autoimmune disease.19
Autoimmune diseases are often associated with an increased prevalence of positive 
testing for antinuclear antibodies (ANA). These auto-antibodies are reactive with anti-
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gens in the nucleoplasm. ANA are probably present in the circulation of all human be-
ings, but the employed test is considered positive when titres are elevated significantly 
above the normal serum level.20 Screening for ANA is one of the diagnostic tests which 
is usually performed if a person is suspected to have a systemic autoimmune disease.21
Anti-neuronal antibodies, often called “onconeural antibodies” given their paraneo-
plastic nature in many cases, are auto-antibodies directed against antigens in the central 
and/or peripheral nervous system. Anti-neuronal antibodies against intracellular anti-
gens in general are not thought to be pathogenic. On the contrary, the anti-neuronal 
antibodies directed against cell surface antigens are themselves disease mediating. 
In contrast to what the name “onconeural” suggests, anti-neuronal antibodies are not 
strictly related to cancer.22
The aim of the present study was to further explore CRPS as a potential auto-antibody-
associated autoimmune process. For this purpose, we compared the prevalence of CRPS 
patients with a positive test for antinuclear antibodies and for anti-neuronal antibodies 
with the prevalence in the healthy population.
MAteRiAlS AnD MethoDS
This study was approved by the Medical Ethics Committee of the Erasmus MC Rotterdam 
(MEC-2012-037).
Patients
Our department, a university Center for Pain Medicine serves as an expert center for CRPS 
patients. Both acute and chronic CRPS patients visit the clinic on their own initiative or 
on referral by GP’s or medical specialists. There is a weekly outpatient clinic especially for 
CRPS patients, led by physicians with clinical and research experience in CRPS.
All patients who visited the Center for Pain Medicine between 2001 and 2007, and 
fulfilled the Harden-Bruehl diagnostic criteria for CRPS23 were invited to participate in 
on-going CRPS studies.
For all patients signs (subjective) and symptoms (objective), i.e., the presence or ab-
sence of allodynia, hyperalgesia, dystonia, bilateral difference in temperature, difference 
in colour, difference in sweating, difference in motor range, difference in strength, were 
recorded.
In each patient who participated in a study, venous blood was drawn. Serum of this 
blood was stored with permission, to use in future research. For the current study, serum 
of 82 patients was available. All these patients were classified as CRPS type 1. The char-
acteristics of the 82 patients are described in table 1.
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laboratory tests
Venous blood samples were centrifuged immediately after collection at 3000 rpm dur-
ing 10 minutes and serum was stored at minus 80 degrees Celsius until use.
Anti-nuclear antibodies (ANA) were determined according to international recom-
mendations24 with a commercially available test system, according to manufacturer’s in-
structions. Briefly, HEp-2000™ cells (Immuno Concepts, Sacramento, CA) were incubated 
with 1:80 diluted patient serum. After washing, bound autoantibody was detected using 
fluorescein (FITC)-conjugated anti-human IgG (Immuno Concepts) and visualized at 
488 nm by fluorescence microscopy. ANA results were considered positive if at least 
weak positive nuclear staining of HEp-2000™ cells was observed. Borderline results were 
discarded.
Anti-neuronal antibodies were determined according to international guidelines25 
with a commercially available test system, according to manufacturer’s instructions.
Briefly, primate cerebellar cryosections (IMMCO Diagnostics, Buffalo, NY) were 
incubated with 1:400 diluted patient serum. After washing, bound autoantibody was 
detected using fluorescein (FITC)-conjugated anti-human IgG (IMMCO Diagnostics) and 
visualized at 488 nm by fluorescence microscopy. Results were considered positive if at 
least weak positive staining of neuronal nuclei (anti-neuronal nuclear antibody, ANNA) 
or Purkinje cells (Purkinje cell cytoplasm antibody, PCA) was observed. Borderline results 
were discarded as well as false positive neuronal nuclear staining in the presence of a 
positive ANA.
Since literature reference varies regarding prevalence of auto-antibodies in healthy 
individuals, mostly due to methodology, we did not use literature reference for compari-
son. Instead, the results of ANA and anti-neuronal antibody obtained in CRPS patients 
were compared to those we obtained ourselves in parallel using serum obtained from 
table 1. Patients’ characteristics
Characteristics n=82
Woman (n,%) 69 (84.1)
Age in years (mean, sd) 44.2 (12.37)
CRPS duration in months (median, IQR) 11 (36-5)
Cold CRPS (n, %) 44 (53.7)
Warm CRPS (n, %) 31 (37.8) 
Unknown (n, %) 7 (8.5) 
Upper limb (n, %) 48 (58.5)
Precipitating injury
Trauma (n, %) 53 (64.6) 
Operation (n, %) 21 (25.6) 
Spontaneous (n, %)  6 (7.3) 
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randomly selected healthy blood bank donors, using identical methodology as de-
scribed above.
Statistical analysis
Descriptive statistics were used to determine the (Multiple Response) frequencies of 
the demographic variables and the outcome parameters and to describe measures of 
central tendency and of variability, dependent on the shape of their distribution. Testing 
for normality of the distributions was performed using the Kolmogorov-Smirnov test. 
The difference between the proportion CRPS patients with positive (nuclear or neuro-
nal) antibodies and that in the healthy population was analysed using the Fisher’s Exact 
Test, 2-sided. The same test was applied to evaluate the difference in proportion of signs 
and symptoms between (1) the patients positive and those negative for anti-nuclear 
antibodies and (2) between the patients positive and those negative for anti-neuronal 
antibodies.
Difference in duration of the CRPS between patients with positive and those with 
negative anti-nuclear antibodies were tested using the Mann-Whitney U test. Analyses 
were performed using IBM SPSS Statistics 21.
ReSultS
Twenty seven (33%) of the 82 included CRPS patients showed a positive result for 
anti-nuclear antibodies. This proportion is significantly higher compared to that in the 
healthy population (n=90), in which we observed 4% ANA positivity (P < .001).
The observed ANA immunofluorescence patterns were diverse, including homoge-
neous, speckled and nucleolar patterns. See table 2.
table 2. IF pattern of Anti-Nuclear Antibodies
Anti-nuclear Antibodies positive n=27
Homogeneous (n, %) 7 (26)
Speckled (n, %) 6 (22)
Nucleolar (n, %) 12 (44)
Homogeneous and nucleolar (n, %) 2 (8)
No statistically significant difference was found in the proportion of patients with an 
ANA positivity between patients with a cold and those with a warm CRPS, respectively 
34.1% and 32.3% (p=0.99). Likewise, no statistically significant difference in duration of 
the CRPS was found between the patients with a positive test for ANA and those with a 
negative test (p=0.66).
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Six (7.3%) of the 82 included CRPS patients showed a positive result for anti-neuronal 
antibodies. This percentage does not deviate from that in the healthy population (7.5%).
As indicated by the immunofluorescence pattern on the cerebellum substrate, the 
majority of reactivity was directed against neuronal nuclei (ANNA). In addition, reactivity 
against Purkinje cell cytoplasm (PCA) was observed. See table 3. However, the immuno-
fluorescence pattern in the healthy population indicated reactivity to basket neurons 
and/or neurofilaments, as opposed to the ANNA and PCA patterns observed in the CRPS 
patients.
table 3. IF pattern of Anti-Neuronal Antibodies
Anti-neuronal Antibodies positive n=6
Neuronal nuclei (n, %) 4 (66)
Purkinje cells (n, %) 1 (17)
Neuronal nuclei and purkinje cells (n, %) 1 (17)
Two patients showed both a positive ANA test (speckled pattern) and a positive result 
for anti-neuronal antibody (ANNA).
No statistically significant differences in signs or symptoms between patients positive 
and those negative for anti-nuclear antibodies were found. The same applied to patients 
positive and those negative for anti-neuronal antibodies. For all proportional differences 
0.13 = p ≤ 1.
DiSCuSSion
To gain more insight in the potential role of systemic and/or organ-specific autoimmu-
nity in the pathophysiology of CRPS, we studied the prevalence of both anti-nuclear 
antibodies (ANA) and anti-neuronal antibodies in CRPS patients.
The reported prevalence of ANA in healthy individuals is up to 20% or more. The 
prevalence of ANA depends, however, on various factors including age, gender and 
methodology.26 Using our method of ANA testing, the prevalence in healthy individuals 
was 4%.
In our CRPS study sample we found a statistically significant higher positive ANA 
prevalence (33%) compared to that in the healthy population. To correct for a pos-
sible confounder age, since the prevalence of positive testing for ANA in the general 
population is higher amongst people aged above 65 years (up to 30%), we excluded the 
CRPS patients aged above 65 years (two patients). The positive ANA prevalence in CRPS 
remained significantly higher, 30%.
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Diverse ANA patterns were observed in CRPS, including homogeneous, speckled and 
nucleolar. Either pattern can be observed in systemic autoimmune disease, but is not 
specific to any particular autoimmune disease.27
The prevalence of anti-neuronal antibodies in CRPS patients was 7.3%, showing 
characteristic ANNA and PCA patterns.25,28 A similar prevalence was found in healthy 
subjects, however showing a clearly different, atypical pattern. The clinical relevance 
of such patterns is unclear, but are observed more often in subjects without apparent 
neurological disease (Schreurs MWJ, unpublished results). Although the immunofluo-
rescence pattern in the healthy population, reactivity to basket neurons and/or neuro-
filaments, was different as compared to the ANNA and PCA patterns observed in CRPS 
patients, this observation may lack meaning due to the low amount of positive patients 
identified.
The phenotype does not seem to be different, because the signs and symptoms did 
not show any significant differences between CRPS patients positive or negative for 
anti-nuclear antibodies, nor for anti-neuronal antibodies.
Our findings suggest that auto-antibodies may be associated with the pathophysiol-
ogy of CRPS, at least in a part of the patients. However, although increased compared 
to the general population, the positive ANA prevalence in CRPS patients is much lower 
than in patients with classic systemic autoimmune disease such as systemic lupus ery-
thematosus (SLE), that shows a prevalence of 99%.21 The positive ANA prevalence in CRPS 
patients is more in line with the 25% observed in patients with autoimmune diseases 
such as rheumatoid arthritis (RA).21 Based on these findings, we may suggest that CRPS 
is more similar to an autoimmune disease as RA than to a systemic autoimmune disease 
as SLE. This hypothesis is supported by studies that revealed associations between CRPS 
and chronic inflammatory disorders, including asthma10 and multiple sclerosis.11 To our 
knowledge there are no reports of strong associations between CRPS and autoimmune 
diseases, although there are two case-reports of co-occurrence of the two disorders in 
one patient.29,30
The presence of anti-neuronal antibodies in CRPS patients has been established in 
earlier research.15,16 In previous studies, antibodies were directed against a neuroblas-
toma cell line. In our current study we used a cerebellum substrate containing both 
afferent and efferent nerve pathways, with sensory and motor function. We chose this 
substrate because it resembles peripheral nerve tissue, which seems to be affected in 
CRPS.31 Therefore, and based on our observation of characteristic ANNA and PCA reactiv-
ity in some patients, our results suggest that autoimmunity against the peripheral nerve 
system could be of relevance in CRPS in a limited subset of cases. Since the majority of 
CRPS patients did not display anti-neuronal antibodies, a causal relationship remains to 
be determined. Alternatively, in the subset of patients with anti-neuronal antibodies, 
their expression might have been a secondary event as a result of nerve damage.32 It 
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would therefore be interesting to search for signs of actual nerve damage in patients 
who display these anti-neuronal antibodies and to search for the actual antigenic 
specificity of the antibodies. To define whether or not anti-neuronal antibodies could be 
causative for CRPS is of clinical relevance, as immune therapies, such as corticosteroids 
and intravenous immunoglobulin have been shown to positively affect the neurological 
outcome when a disorder is caused by an anti-neuronal antibody directed against a 
cell surface antigen.22 Interestingly, previous work has already shown that some CRPS 
patients do respond to intravenous immunoglobulin treatment.18
Before speaking of clear evidence of an autoimmune etiology, Witebsky’s criteria for 
an autoimmune disease should be considered.33 These criteria include: 1) demonstra-
tion of a specific antigen; 2) circumstantial evidence of an autoimmune or inflammatory 
disorder from clinical clues; and 3) reproduction of clinical features in recipient animals 
by passive transfer of putatively pathogenic antibodies. We argue that CRPS definitely 
meets the second criterion. There are indications that the first criterion is met as well, 
however this applies only to some of the CRPS patients. And more research is needed 
to define specific antigens involved. Injection of serum-IgG from a CRPS patient into 
groups of mice showed abnormal physical behavior and a significant reduction in rear-
ing.34 However, these findings are not a reproduction of the clinical features, as needed 
for the third criterion. Therefore, although suggestive, it remains uncertain whether 
CRPS can be defined as an autoimmune disease.
In conclusion, our findings indicate an autoimmune-related pathophysiology of CRPS 
in at least a subgroup of CRPS patients. Further research is needed into defining this 
subset and into the role of antibodies in the pathogenesis of CRPS in these patients.
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AbStRACt
background
Different mechanisms are involved in a complex network of interactions resulting in the 
painful and impairing disorder CRPS. There is convincing evidence that inflammation 
plays a pivotal role in the pathophysiology of CRPS. Immunomodulating medication 
reduces the manifestation of inflammation by acting on the mediators of inflammation. 
Therefore, as inflammation is involved in the pathophysiology of CRPS, immunomodu-
lating medication in CRPS patients may prove beneficial.
objectives
To describe the current empirical evidence for the efficacy of administering the most 
commonly used immunomodulating medication (i.e. glucocorticoids, TNF-α antago-
nists, thalidomide, bisphosphonates and immunoglobulins) in CRPS patients.
Methods
PubMed was searched for original articles which investigated CRPS and the use of one 
of the above-mentioned immunomodulating agents.
Results
The search yielded 39 relevant articles: from these, information on study design, sample 
size, duration of disease, type and route of medication, primary outcome measures and 
results was examined.
Discussion
Theoretically, the use of immunomodulating medication could counteract the ongoing 
inflammation and might be an important step in improving a disabled hand or foot, 
leading to further recovery. However, more high-quality intervention studies are needed.
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intRoDuCtion
Complex regional pain syndrome (CRPS) is a complication after surgery or trauma, but 
spontaneous development is also described. It was formerly known by many names, but 
was most commonly referred to as ‘reflex sympathetic dystrophy’ (RSD).
The diagnosis of CRPS is based on signs and symptoms. Of the several diagnostic 
criteria sets available, the most used are the Veldman1, the IASP2 and the ‘Budapest 
Criteria’.3
Most patients have a burning spontaneous pain, disproportionate in intensity to the 
initial eliciting event, most often being a fracture of an extremity.4 In the acute stages of 
CRPS the affected limb is generally warmer than the contralateral limb, with edema as 
a common symptom. Hypo- or hyperhidrosis is present in many patients. About 70% of 
the patients have weakness of all muscles in the affected region and a decrease in the 
active range of motion. The upper extremities are affected more frequently than the 
lower extremities.5
The estimated overall incidence rate of CRPS is 26.2 per 100,000 person years.5 Fe-
males are affected at least three times more often than males. The highest incidence 
occurs in females in the age category of 61-70 years.5
It is reasonable to assume that different mechanisms are involved in a complex 
network of interactions, resulting in the painful and impairing disorder of CRPS.6 CRPS 
often displays the classic aspects of inflammation.1 There is convincing evidence that 
inflammation is one of the mechanisms playing a pivotal role in the pathophysiology 
of CRPS.6 The presence of local inflammation was shown in a scintigraphic study on 
CRPS in which vascular permeability for macromolecules was demonstrated.7 Increased 
systemic CGRP levels in patients with acute CRPS suggest neurogenic inflammation as a 
pathophysiologic mechanism.8 Increased levels of the pro-inflammatory cytokines have 
been detected in fluid from artificially raised skin blisters in the involved extremity in 
comparison to the contralateral site; however, no correlation was found between levels 
of pro-inflammatory cytokines and the characteristics or duration of the disease.9-12 
This is an indication that inflammation explains a part, but not the whole picture of the 
pathophysiology.
Analysis of blister fluid with a multiplex array (testing for 25 different cytokines) 
revealed a pro-inflammatory expression profile, with increased markers for activated 
monocytes and macrophages.13 Also, a pro-inflammatory cytokine expression profile 
was demonstrated in the cerebrospinal fluid of CRPS patients.14 Venous blood of patients 
with CRPS showed elevated mRNA levels of the pro-inflammatory cytokines TNF and IL-2 
and serum IL-2 protein, as well as a reduction of mRNA levels of the anti-inflammatory 
cytokines IL-4 and IL-10.15 Plasma demonstrated higher levels of soluble TNF-α recep-
tor.16 After performing technetium 99m-anti-TNF-α antibody scintigraphy, a recent case 
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report showed that TNF-α was only localized in the affected hands of patients with early 
CRPS.17 In addition, the contribution of inflammation in the pathophysiology of CRPS 
is suggested by the successful reports from open-label studies on treatment with im-
munomodulating agents such as infliximab18 and immunoglobulin.19
Immunomodulating medication reduces the manifestation of inflammation by 
influencing mediators of inflammation, such as cytokines, neuropeptides, eicosanoids 
and amino acids. If inflammation does play a role in the pathophysiology of CRPS, then 
immunomodulating medication may be beneficial for CRPS patients.
Despite the fact that, especially in higher doses, nonsteroidal anti-inflammatory 
drugs (NSAIDs) also show anti-inflammatory effects, these drugs are not included in 
the group of immunomodulating medications. For this reason, we disregarded them 
from this review. In general we know that NSAIDs have no effect in the CRPS.20 In the 
Netherlands there is some popularity for treating CRPS with free radical scavengers.21 
Due to a lack of convincing evidence for effectiveness, these drugs never gained general 
international acceptance. For this study we decided to exclude them.
This review presents the current empirical evidence for the benefit of administering 
the most commonly used immunomodulating drugs in CRPS patients.
glucocorticoids
Glucocorticoids are anti-inflammatory by preventing phospholipid release, decreasing 
eosinophil action and a number of other mechanisms. Interactions between the ner-
vous system, the hypothalamic-pituitary-adrenal axis, and components of the innate 
and adaptive immune system play a key role in the regulation of inflammation and 
immunity. Glucocorticoids can also inhibit prostaglandin production through some 
independent mechanisms.22
tumor necrosis factor-α antagonists
Tumor necrosis factor alpha (TNF-alpha) is a cytokine which promotes an inflamma-
tory response. Although principally produced by macrophages, other cells (including 
lymphocytes and mast cells), and tissue cells (such as epithelial cells and fibroblasts) can 
also secrete TNF.23 The possible mechanism of action of anti-TNF agents are inhibition 
of inflammatory ‘cytokine cascade’ mediated by TNF; sequestration of TNF by binding; 
complement-mediated lysis of cells expressing TNF; altered leukocyte recruitment and 
endothelial activation; reduction of vascular endothelial growth factor expression and 
neovascularization; restoration of function of regulatory T cells, and induction of T lym-
phocyte apoptosis.
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thalidomide
Thalidomide inhibits TNF-α production by human blood monocytes, without influenc-
ing either general protein synthesis or the expression of three other monocyte-derived 
cytokines. Thalidomide exerts a selective effect by suppressing only TNF-α secretion, 
neither IL-1β, IL-6, nor granulocyte macrophage colony-stimulating factor production 
is influenced by the drug.24 Thalidomide was introduced as a sedative drug in the 
late 1950s. It was withdrawn from the market in the early 1960s due to teratogenicity 
and neuropathy. There is growing interest due to its immunomodulatory properties. 
Thalidomide is also a potent inhibitor of new blood vessel growth.25 On the basis of 
this finding clinical trials were initiated, which have reported its effectiveness against 
multiple myeloma.26
bisphosphonates
The most important biological effect of bisphosphonates is the reduction of bone re-
modeling through the inhibition of osteoclastic activity, but there is evidences of extra-
skeletal biological effects of bisphosphonates.27 Bisphosphonates exert their effects 
also on cells of the immune system with an “immunomodulating” effect, influencing 
the production of pro- and anti-inflammatory cytokines and changing the molecular 
expression involved in the immune process and anti-inflammatory response. The exact 
identification of target cells and interference mechanisms of bisphosphonates with the 
immune and inflammatory responses are not yet totally clear.
immunoglobulins
The mechanism of action of immunoglobulins involves modulation of expression and 
function of Fc receptors, interference with activation of complement and the cytokine 
network, provision of anti-idiotypic antibodies, regulation of cell growth, and effects 
on the activation, differentiation, and effector functions of dendritic cells, T and B 
cells.28 Modulation of the production of cytokines and cytokine antagonists by intra-
venous immunoglobulin is a major mechanism by which immunoglobulin exerts its 
anti-inflammatory effects. The anti-inflammatory effects are not restricted to monocytic 
cytokines, but are also largely dependent on the ability of intravenous immunoglobulin 
to modulate Th1 and Th2 cytokine production.
MAteRiAlS AnD MethoDS
The PubMed database was searched from inception up to end August 2010. The search 
was for original articles (in the English language) which met our criteria. The initial 
search strategy included ((complex regional pain syndrome [Title/Abstract] OR reflex 
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sympathetic dystrophy [Title/Abstract]) AND (glucocorticoids/steroids [Title/Abstract]) 
OR (TNF-α antagonist/anti-TNF [Title/Abstract]) OR (thalidomide [Title/Abstract]) OR 
(bisphosphonate/biphosphonate [Title/Abstract]) OR (immunoglobulin [Title/Ab-
stract])).
The abstracts of retrieved articles were manually reviewed to assess suitability for 
inclusion using the following criteria: adult humans having CRPS (the previously used 
names for this syndrome were also allowed, e.g. shoulder-hand syndrome, RSD), to-
gether with the use of one of the abovementioned immunomodulating medications. 
The references of the selected articles were also checked for additional relevant papers.
Finally, from all studies fulfilling the inclusion criteria the following information was 
examined: type of study, sample size, duration of disease, type and route of medication, 
primary outcome measures, and results.
ReSultS
The literature search yielded 39 articles, 10 case reports, 19 observational studies, and 10 
randomized controlled trials (RCTs: 7 blinded and 3 non-blinded).
The results of the various medications are described below (and in Table 1).
glucocorticoids
A total of 3 case reports, 13 open-label studies and 5 RCTs (2 of which blinded) were 
found.
The 3 case reports described 5 patients: in all cases the signs and symptoms improved 
after administration of glucocorticoids.29-31
In the 13 open-label studies, various dose regimens were prescribed and different 
routes of administration were used.32-44 In 3 of the open-label studies, patients who 
received medication were analyzed, as were those who received stellate ganglion 
blockade, physiotherapy, or no specific treatment. These treatments were then com-
pared with each other.33, 34, 38 Although the results of the open-label studies were based 
on different parameters, like clinical improvement and visual analog scale, the use of 
glucocorticoids seems to cause predominantly improvement in outcome. Only one of 
these studies described 2 major adverse events (arterial occlusion below the femorals 
and manic psychosis33); in the remaining studies only minor events (e.g. weight gain) 
were described.
Of the 5 RCTs45-49 2 were double-blinded.47,49 The first double-blinded study showed 
no improvement of CRPS using a Bier block with methylprednisolone compared with 
placebo.47 The second study, in which patients received medication intrathecally, was 
stopped early owing to no effect after interim analysis.49
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In 2 of the remaining 3 non-blinded RCTs, use of glucocorticoids resulted in a signifi-
cantly greater improvement in activity of CRPS45 or in shoulder-hand syndrome score46 
compared with placebo. The third RCT showed a significantly greater improvement in 
the signs and symptoms of CRPS among patients receiving glucocorticoid compared 
with those receiving piroxicam.48
In 3 of the 5 RCTs, the patients suffered from CRPS for a period of about 3 months.45, 47, 48 
In another study, patients suffered for a mean duration of 4.5 years,49 and in 1 study 
the duration of disease was not reported.46 The studies used different primary outcome 
measures. In 1 RCT, the placebo group could also receive medication afterwards46 
(Table 1). In contrast to the open-label studies, no serious side-effects were described.
tnf-α antagonists
Two case reports were found describing 3 patients.18, 50
All 3 patients received infliximab and showed improvement in pain, temperature 
and motor function. The 2 patients who had CRPS for 2 to 3 months showed greater 
improvement than patients with CRPS for 5 years. No adverse effects were observed.
thalidomide
Two case reports and 1 open-label study were found.
In the case reports, thalidomide was introduced for CRPS patients with a comorbid con-
dition.51, 52 In this case thalidomide had a beneficial effect on CRPS. In the open-label study 
42 patients were treated.53 A “dramatic response” occurred in 17% of the patients, and 14% 
experienced at least modest pain relief and/or showed some reduction in the need for 
concurrent medications. No results for the remainder of the patients were reported.
In 1 patient, due to persistent paresthesia, thalidomide was temporarily stopped after 
which the pain re-occurred.52 Although patients often felt worse during the first weeks 
of therapy (e.g. increased pain and edema) no major side-effects were reported.
bisphosphonates
Two case reports, 4 open-label studies, and 4 double-blind RCTs were found.
In the case reports the 2 patients experienced pain relief.54, 55
In the open-label studies pamidronate or ibandronate was used.56-59 These studies 
reported a positive effect of both drugs on pain intensity.
Patients who participated in the RCTs were prescribed alendronate (oral or intrave-
nous)60,61, clonadrate62 or pamidronate.63 All were compared with placebo. In 2 of the 
RCTs, patients had CRPS for less than 6 months61, 62, compared with about 7 months to 
6 years in the other 2 studies.60, 63 In all RCTs there was a significant decrease of pain. 
Apart from pain, the other primary outcome measures were different but all showed 
improvement. Three RCTs were followed by an open-label study in which continuation 
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of the medication showed an additional effect; however, the difference was not signifi-
cant.60-62
Side-effects were minimal (e.g. transitory flu-like symptoms); 1 patient dropped-out 
of one of the trials due to upper gastrointestinal intolerance.60 No serious adverse events 
were described.
immunoglobulin
The search yielded 1 case report, 1 open-label study, and 1 double-blinded RCT.
In the case report the patient recorded more than 50% pain reduction, accompanied 
by cessation of autonomic signs.19 In the open-label study, only 11 of the 130 described 
patients were suffering from CRPS,64 in the total group of patients, 20% had more than 
70% pain relief, and 27.7% reported pain relief ranging from 25 to 70% relief.
The RCT was a double-blind, randomized, placebo-controlled study.65 Patients re-
ceived either the intervention in the first period and placebo in the second, or placebo 
in the first period and the intervention in the second. Pain intensity was the primary 
outcome measure and was 1.55 units lower after treatment with immunoglobulins com-
pared with placebo. The treatment was associated with very few adverse events, except 
for moderate or severe headache and transient pain increase. No serious adverse events 
were reported.
DiSCuSSion
This literature review was conducted to assess empirical evidence for the efficacy of 
various immunomodulating medication in CRPS patients.
The assessment is complicated by the fact that the cited studies show extensive 
methodological variability, that is, presence or absence of a control group, use of differ-
ent designs, and varying sample compositions, diagnostic criteria and primary outcome 
measures. The exact impact of the outcome is often unclear.
The CRPS criteria applied for diagnosis vary between studies. The most common 
criteria are the IASP criteria66, a revision of the criteria set has been proposed for both 
diagnostic and research purposes.67 Because different criteria for diagnosing CRPS were 
used in the studies in this review, it is unlikely that all patients in these studies are com-
parable.
The studies covered the treatment of both acute and chronic conditions. A scinti-
graphic study to investigate whether inflammatory characteristics are present showed 
significantly more patients with early CRPS (existing for ≤ 5 months) with a positive scin-
tigraphy compared with patients who had CRPS for a longer period.7 Also, although the 
presence of local inflammation was confirmed in the first 2 years of CRPS, cytokine levels 
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did not correlate with either the characteristics or duration of the disease.10 Therefore, 
the acute versus chronic classification is probably inadequate, and the time factor thus 
becomes less important.
It seems difficult to determine the appropriate period for treatment with immuno-
modulating medication. It seems more important to determine in each patient whether 
or not there is still an (ongoing) inflammatory process.
In addition, different primary outcome measures were used in the studies. In none of 
the studies was an improvement in inflammation measured. We suggest that a selection 
of 2 or 3 representatives from the inflammatory cytokines panel, the Th1/Th2 cytokines 
panel and the chemokines panel would be sufficient to indicate the activity of the 
CRPS disease; during the course of the disease this selected panel could also be used 
to indicate the effectiveness of therapeutic intervention.13 This might allow to better 
determine which patients are likely to benefit from treatment with immunomodulating 
drugs.
Because the studies have different designs, the degree of empirical evidence yielded 
also differs. Most of the included articles were case reports or uncontrolled open-label 
studies. On the basis of these studies, TNF-α antagonists and thalidomide were reported 
to have a positive effect. Noteworthy, an open-label study, in which CRPS patients 
received lenalidomide (a thalidomide analog), showed that lenalidomide’s pain and 
functional improvement sustained over 52 weeks of treatment. There would be some 
serious adverse events, suspected to be related to lenalidomide. However, this study 
only appeared in a poster presentation at a congress, and these results have not been 
published.68
The immunoglobulins were also investigated by means of a randomized double-
blind placebo controlled trial; this trial also showed a positive effect, albeit a small one. 
However, for the glucocorticoids and bisphosphonates more RCTs have been performed. 
The glucocorticoids yielded 5 RCTs, of which the 2 blinded RCTs showed no benefit. 
However, a disadvantage is that the intervention in these 2 latter studies was admin-
istered by means of a Bier block, or intrathecally. In contrast, in the non-blinded trials, 
the oral glucocorticoids had a positive effect. Oral and intravenous bisphosphonates 
also appeared to have a positive effect. In our opinion, the use of bisphosphonates can 
be recommended; however, which medication, which dose, and for how long remains 
unclear. Our recommendation is in contrast to another group who also reviewed the 4 
RCTs of bisphosphonates,69 they concluded that, although bisphosphonates have the 
potential to reduce pain, there is insufficient evidence to recommend their use.
In summary, there is increasing evidence to show that inflammation does play a role 
in the pathophysiology of CRPS. Immune involvement brings a mechanism-based treat-
ment within reach. On the basis of the results of this review, the use of immunomodulat-
ing medication may counteract the ongoing inflammation and might be an important 
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step in the recovery of the disabled hand or foot. However, as might be evident from the 
studies described above, this literature is of a very poor quality. Therefore, there is a need 
for more high-quality intervention studies.
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AbStRACt
objective
Inflammation appears to play a role in CRPS as, for example, cytokines (like TNF-α) are 
involved in the affected limb. The ongoing inflammation is probably responsible for 
the central sensitization that sometimes occurs in CRPS. Thus, early start of a TNF-α 
antagonist may counteract inflammation, thereby preventing rest damage and leading 
to recovery of the disease.
Design
Patients (n=13) were randomly assigned to infliximab 5mg/kg or placebo, both admin-
istered at week 0, 2, and 6.
outcome measures
The aim was to confirm a reduction in clinical signs of regional inflammation (based 
on total impairment level sumscore: ISS) after systemic administration of infliximab. 
Also, levels of mediators in the fluid of induced blisters were examined in relation to 
normalization and improvement in quality of life.
Results
Six patients received infliximab and 7, placebo. There was no significant change in total 
ISS score between the two groups. Similarly, no significant difference in change in cy-
tokine levels was found between infliximab compared to placebo. However, there was 
a trend toward a greater reduction of TNF-α in the intervention group compared to the 
placebo group. A subscale of the EuroQol (ie EuroQol VAS) revealed significant decrease 
in health status in the intervention group compared with the placebo group.
Conclusions
This study was terminated before the required number of participants had been reached 
for sufficient statistical power. Nevertheless, a trend was found toward an effect of inflix-
imab on the initially high TNF-α concentration.
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intRoDuCtion
Complex regional pain syndrome (CRPS) is a disabling disease that usually occurs as 
a complication in an extremity after trauma or surgery. However, spontaneous devel-
opment is also described. CRPS is characterized by spontaneous pain, allodynia, and 
hyperalgesia. The pain is disproportionate to the precipitating injury. Additional clinical 
signs include edema, disturbed blood flow to the skin or abnormal sudomotor activity, 
motor dysfunction, and trophic changes in the affected limb. The clinical picture was 
first described more than 100 years ago by Sudeck. Based on a consensus meeting of the 
IASP in 1993, the term ‘complex regional pain syndrome’ has been agreed upon.1
The estimated incidence ranges from 5.46 to 26.2 per 100,000 person-years. CRPS in 
adults most often occurs in the upper extremities, and a fracture is the most common 
initial event. Women are affected 3.4-4 times more often than men. The mean age at 
diagnosis is similar in men and women and ranges from 47 to 52 years.2
The acute phase appears to be a disorder of exaggerated neurogenic inflammation 
with increased skin temperature, edema, redness, pain, and loss of function (the so-
called warm dystrophy).3 These signs and symptoms may be part of the normal physi-
ological response of the body after a trauma and in most patients resolve after a while. 
In CRPS patients, however, they may even become aggravated. This is suggestive of an 
insufficient remission of inflammation in CRPS, which may be one of the initial patho-
genic factors. There is evidence of a pro-inflammatory profile in CRPS with an increase 
in neuropeptides, cytokines, and other mediators of inflammation4-10, which may induce 
pain and hyperalgesia by direct and indirect mechanisms. The concept of a pathophysi-
ological role of cytokines in CRPS is further supported by reports of successful treatment 
for CRPS with an anti-TNF agent, infliximab.11
The possible mechanism of action of anti-TNF agents are inhibition of inflammatory 
‘cytokine cascade’ mediated by TNF; sequestration of TNF by binding; complement-me-
diated lysis of cells expressing TNF; altered leukocyte recruitment and endothelial activa-
tion; reduction of vascular endothelial growth factor expression and neovascularization; 
restoration of function of regulatory T cells, and induction of T lymphocyte apoptosis.12
Furthermore, continuing inflammation is probably responsible for central sensiti-
zation and neuroplastic changes in the spinal cord and higher centers of the central 
nervous system, expressing itself in allodynia, hyperalgesia, autonomic nervous system 
disturbances, and dystonia.9
The use of anti-TNF might counteract the ongoing inflammation and be an important 
step toward restoring the mobility of the disabled hand or foot, leading to further recov-
ery of the disease. Given in an early stage, anti-TNF may also prevent the central changes 
in the nervous system, thereby reducing a change on rest damage.
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The main aim of the present study was to test the hypothesis that systemic adminis-
tration of infliximab would reduce the clinical signs of regional inflammation in the CRPS 
hand or foot. The secondary aims were improvement in the subjective scores of quality 
of life and normalization of the levels of inflammatory mediators in fluid of induced 
blisters.
The trial was registered as ISRCTN75765780.
This study is an investigator-initiated study performed by our research group, that is, 
Center for Pain Medicine of the Erasmus Medical Center, sponsored by Centocor, Inc. The 
company gave a grant for the drug and placebo. Centocor, Inc. was in no way involved in 
the design, performance and analysis of the study, and writing of this article. Performing 
the study, we had a serious recruitment problem that resulted in the decision of Cen-
tocor, Inc. to stop the sponsoring of the study. Unfortunately, the costs of the drug and 
placebo were too high to continue independently. Despite the early discontinuation, we 
think that it is important to share the available data with the scientific world. Those data 
are important for new insight in the pathophysiology and the design of new studies. 
Moreover, we think it is unethical to the patients who participated in the study not to 
make use of those data.
MethoDS
The goal was to include 24 patients with CRPS in one extremity, recruited from a number 
of collaborating pain treatment clinics in the south-western part of the Netherlands and 
enrolled in one center in Rotterdam.
The diagnosis of CRPS was confirmed according to the IASP criteria.13 The following 
were inclusion criteria: (1) patients should have untreatable inflammatory signs during 
recently developed CRPS (> 3 months and <12 months after the initial trauma), (2) they 
should be considered eligible according to the tuberculosis screening criteria set, (3) 
patients should have no previous administration of infliximab and should not be us-
ing drugs which suppress formation of inflammatory mediators, such as corticoids and 
nonsteroid anti-inflammatory drugs (NSAIDs).
The included patients were randomly assigned in a sequential fashion to one of the 
following treatment groups: Group I infliximab (5 mg/kg) in saline solution (0.9%); Group 
II placebo as saline solution (0.9%). Randomization was done in a 1:1 ratio in blocks 
of 4 patients for active and placebo treatments, respectively. The randomization was 
performed by the clinical pharmacy department of the Erasmus Medical Center using a 
computer generated random list. This department also prepared the drugs. Infliximab 
or placebo was administered intravenously at weeks 0, 2 and 6. Both groups received 
physiotherapy once a week, as well as instructions for personal daily exercise.
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The protocol was approved by the Medical Ethics Committee of the Erasmus Medical 
Center Rotterdam (MEC no. 2004-341) and the study was conducted according to the 
Guidelines of the Declaration of Helsinki and for Good Clinical Practice.
The primary outcome parameter was the reduction in clinical signs of regional inflam-
mation in the CRPS hand or foot. The secondary outcome parameters were improvement 
in the subjective scores of quality of life and normalization of the levels of inflammatory 
mediators in fluid of induced blisters.
evaluation of change in regional inflammation
To assess the effect on regional inflammation, the total impairment level sumscore (ISS)14 
was measured. The ISS almost completely reflects the five typical signs of inflammation, 
that is, redness, swelling, increased temperature, pain, and dysfunction. The evaluation 
was performed at screening (visit 1) and at week 10 (study end = visit 10).
Edema (volume by displacement)
Difference in volume was assessed by a volumeter (measuring the displacement of fluid 
by immersion of a body part). The difference between the involved and contra-lateral 
extremity was calculated as a percentage of the contra-lateral extremity. Normal asym-
metry in volume should be less than 2% between both extremities.
Difference in skin surface temperature (videothermography)
Temperature difference between the involved and contra-lateral extremity was measured 
by computerized videothermography. This resulted in a mean difference and a calculated 
asymmetry factor. A normal asymmetry factor should be between 0.90 and 1.00.
Pain (VAS)
The amount of pain was measured with a visual analogue scale (VAS) in millimeters 
(range 0-100, from no pain to most intense pain).
Pain intensity (McGill Pain Questionnaire)
Pain intensity was evaluated with the McGill Pain Questionnaire Dutch Language Ver-
sion (MPQ-DLV). The MPQ is the gold standard against which other measures of pain 
are tested. Patients are presented with 80 adjectives in groups, and they select one from 
each group that most closely matches their own pain. The weighted scores are added to 
produce a total score.
Mobility (active range of motion)
Mobility was measured by the difference in the active range of motion (AROM) of pre-
defined joints in the involved and contra-lateral extremity. AROM is defined as the arc of 
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motion with muscle power to achieve the motion of a joint. In the upper extremity, the 
AROM is measured for the dorsal/palmar flexion of the wrist and for the flexion/exten-
sion in the metacarpophalangeal and proximal interphalangeal joints of the two most 
restricted digits. In the lower extremity, the AROM is measured for the flexion/extension 
in the knee, ankle, and digit 1 of the foot and the inversion and eversion of the ankle.
inflammatory mediators in skin blister fluid
Infliximab directly affects local levels of TNF-α and may therefore influence the TNF-α-
induced process. To determine whether this occurs, levels of TNF-α were measured in 
skin blister fluid. Suction blisters were made on the involved and contra-lateral extremi-
ties.9 The assessment was performed at screening and at week 10.
Other mediators were also measured. A selection of two or three representatives from 
the inflammatory cytokines panel, the Th1/Th2 cytokines panel, and the chemokines 
panel would be sufficient to indicate the activity of the CRPS disease.15
Quality of life (euroQol, Sf-36 health Survey questionnaire, SCl-90)
To assess the effect of treatment on quality of life, the EuroQol, SF-36 and SCL-90 ques-
tionnaires were used. The assessment was performed at screening and at week 10.
Safety evaluation
Safety was evaluated based on adverse events (reported and observed) and on clinically 
significant changes in laboratory values (chemistry profile, and complete blood count 
including differential and platelet counts).
Statistical analysis
Sample size consideration. Based on our data in 46 patients9,10,16 we estimate that the 
screening value of the ISS will be 37.0 with a standard deviation of 5.3. Assuming inde-
pendency of the standard deviation of the group differences with by SQRT 2 times the 
standard deviation of the baseline assessment, considering a significance of 0.05 and a 
power of 80%, and an expected difference of 10% between the pre- and post-treatment 
measurement in the placebo group and an expected difference of 40% between the 
pre- and post-treatment measurement in the infliximab group, 24 patients (2 x 12) 
should be included in the study.
All continuous variables were summarized by including the number of observations, 
mean, standard error of the mean (SEM), and the median. The relation between two 
dichotomous variables was tested using Fisher’s exact test (two-sided). Differences be-
tween the affected side and the contra-lateral side within a specific group were tested 
using the Wilcoxon Rank Test.
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Because of the small number of patients, the efficacy of infliximab was evaluated by 
calculating for all endpoint variables, the change in scores from visit 1 (screening) to visit 
10 (end of study) in both groups. Change in the intervention group compared with the 
placebo group was evaluated using the nonparametric test for independent samples 
(Mann-Whitney U-test, two-sided).
ReSultS
Patients were included between January 2006 and December 2007. After 2 years, the 
recruitment was stopped; many otherwise eligible patients had an exclusion criterion 
(e.g. use of NSAIDs) or many declined to participate (mainly due to fear of side effects).
Finally, 13 patients with CRPS participated: 6 in the intervention group and 7 in the 
placebo group (Figure 1; CONSORT Diagram). All patients had continuing pain, as well as 
a history of hyperesthesia, asymmetry of skin color, edema and dysfunction. All patients 
fulfilled the IASP criteria. Demographic and disease-related baseline characteristics 
showed no significant difference between the two groups. Table 1 presents these pa-
tient characteristics.
table 1. Characteristics of the study population
Patient characteristic intervention Placebo
Gender: male/female 0/6 0/7
Mean age in years (range) 43.75 (25.15-56.87) 52.71 (34.33-70.94)
Affected extremity: arm/leg 4/2 4/3
Affected side: right/left 4/2 2/5
total iSS
The change in volume, and difference in skin temperature and/or AROM between the 
involved and the contra-lateral extremity showed no significant difference between the 
two groups. Also, for pain intensity there was no significant decrease in or between the 
two groups. Pain scores (VAS) were found to decrease between visit 1 and visit 10 in 
both groups. However, the decrease in current pain did not significantly differ between 
both groups.
Thus, in these patients, there was no significant decrease in total ISS in the interven-
tion compared with the placebo group. This result is complicated by the fact that the 
data concern (in total) eight arms and five legs.
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inflammatory mediators in skin blister fluid
Table 2 and Figure 2 present data for all participants on cytokine levels of the involved 
vs. the contra-lateral extremity as measured at visit 1 and visit 10.
At visit 1, the levels of three cytokines in the involved extremity were compared with 
the contra-lateral extremity, that is, TNF-a (pg/ml) (Z = −2.578, P = 0.10), IL-8 (pg/ml) (Z = 
−2.667, P = 0.008), and Rantes (pg/ml) (Z = −2.312, P = 0.02). In addition, another cyto-
kine showed a trend toward a higher level in the involved extremity at visit 1 compared 
with visit 10, that is, IP-10 (pg/ml) (Z = −0.778, P = 0.08).
The effect of the intervention was analyzed by testing the difference in cytokine 
levels between the placebo and intervention group at visit 10 compared with the differ-
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figure 1. CONSORT: anti-TNF-α in CRPS
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ence in levels at visit 1. No significant differences were found in the change in cytokine 
levels between the two groups. However, a trend was found toward a larger reduction in 
the level of TNF-a (pg/ml) in the intervention group compared with the placebo group 
(P = 0.07).
Quality of life (euroQol, Sf 36 health Survey questionnaire, SCl-90)
In the intervention group, the EuroQol VAS score at visit 1 was increased compared with 
that at visit 10, whereas in the placebo group the effect was neutral; this difference in 
change over time between the two groups was significant (P = 0.03) (Table 3). In other 
words, compared to placebo the health status in the intervention group became signifi-
cantly worse.
For the remaining EuroQol subscales scores, no significant differences over time were 
found between the groups. Furthermore, no significant difference (or a trend toward it) 
was found in the scores of the other outcome parameters.
figure 2. TNF-α (pg/ml) at screening and at end of the study by side and by study group
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Safety evaluation
During this trial, one serious adverse event was reported. This concerned a patient in 
the placebo group who was involved in a car accident four months after completion of 
the study. She suffered multiple fractures and was hospitalized, followed by treatment 
in a rehabilitation center. The relationship to the treatment was classified as ‘other’. No 
serious adverse events were reported in the intervention group.
Registration of all other adverse events revealed 28 in the infliximab group and 51 in 
the placebo group. Examples of adverse events in the infliximab group are one patient 
with increased blood pressure during infusion, and headache, dizziness, diplopia, and 
nausea in the days thereafter; another patient reported constipation, a light headache, 
malaise, flu-like symptoms, and episodes with a herpetic lip during 1 year; and one 
patient reported flu-like symptoms.
table 3. EuroQol subscale scores
Subscale Visit 1 (Screening) Visit 10 (End of study)
Intervention Placebo Intervention Placebo
Mobility (walking) No problems 4 (66.67%) 4 (57.14%) 3 (50.0%) 4 (57.14%)
Some problems 2 (33.33%) 3 (42.86%) 3 (50.0%) 3 (42.86%) 
Bedridden 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 
Self care (wash/
dress yourself )
No problems 3 (50.0%) 2 (28.57%) 2 (33.33%) 3 (42.86%)
Some problems 3 (50.0%) 5 (71.43%) 4 (66.67%) 4 (57.14%) 
Unable 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 
Daily activities No problems 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
Some problems 5 (83.33%) 7 (100%) 6 (100%) 7 (100%) 
Unable 1 (16.67%) 0 (0.00%) 0 (0.00%) 0 (0.00%) 
Pain or other
complaints
No 0 (0.00%) 0 (0.00%) 0 (0.00%) 0 (0.00%)
Moderate 3 (50.0%) 5 (71.43%) 4 (66.67%) 5 (71.43%) 
Very severe 3 (50.0%) 2 (28.57%) 2 (33.33%) 2 (28.57%) 
Mood (Anxious or
depressed)
No 5 (83.33%) 4 (57.14%) 4 (66.67%) 5 (71.43%)
Moderately 1 (16.67%) 2 (18.57%) 1 (16.67%) 2 (28.57%) 
Severely 0 (0.00%) 1 (14.29%) 1 (16.67%) 0 (0.00%) 
EuroQol-5D Mean (SEM) 0.40 (0.14) 0.41 (0.10) 0.43 (0.16) 0.50 (0.10)
Median 0.41 0.59 0.66 0.66 
EQ-5D VAS score* Mean (SEM) 71.67 (7.82) 50.71 (2.77) 45.33 (15.3) 62.43 (7.72)
Median 75 50 46.5 50 
* Difference in EQ-5D VAS score visit 10 vs. visit 1; P = 0.03
SEM = standard error of the mean
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DiSCuSSion
From the start of the study, there were problems with recruiting patients. We tried to 
improve this by collaborating with anesthesiologists throughout the south-western 
part of the Netherlands, by giving lectures to patient organisations and to the Dutch 
CRPS patient organisation, by advertising on the website of the patient organisation, 
and by distributing newsletters to family doctors, neurologists and anesthesiologists in 
the region.
We assume several reasons why so few patients could be included. First, after publica-
tion of the Dutch CRPS guidelines in 2006, many family doctors and peripheral specialists 
have the tools to treat acute CRPS patients (e.g. with vitamin C, fluimucil or DMSO). We 
clearly see a decline in the referrals after the publication of this guideline. Only patients 
who did not respond to this initial therapy were later referred to our clinic to (perhaps) 
participate in this trial. Although we tried to minimise the delay before the visit to the 
clinic, there were always more complicated/chronic CRPS patients available than acute 
CRPS patients. Many of these sub-chronic patients exceeded the inclusion criterion of a 
maximum of 12 months after the initial trauma.
Several eligible patients declined to participate: some because they considered 
placebo treatment to be a risk and others because they expected their symptoms to 
improve without the offered medication.
On reflection, excluding patients using NSAIDs is perhaps too academic. These drugs 
were not allowed because they might suppress formation of inflammatory mediators. 
However, these drugs affect prostaglandins and not cytokines like TNF-α.
In this relatively small study, we found an indication for effect on the inflammatory 
mediator TNF-α and a significant deterioration on a subscale of quality of life, but not 
on the other parameters. We cannot explain this deterioration. It could be an accidental 
finding by multiple testing or because of sampling variation.
There was an interesting decrease in the inflammatory mediator. Figure 2 shows that, 
at screening, TNF-α is higher on the involved side than on the contra-lateral side. This is in 
accordance with our earlier work9-11, 17 and was the rationale for this study with infliximab. 
After infliximab, TNF-α was reduced to less than 2 pg/ml. TNF-α was also reduced in the 
placebo group, but to values of about 30 pg/ml. It is unclear what caused this reduction; 
perhaps the initial inflammation reduced during the natural course of the disease.
In the acute phase of CRPS neuroinflammation occurs, where free radicals inflict damage 
on several local tissues.18,19 Furthermore, changes in neuroplasticity and central sensiti-
sation have been described. Thus, even when the inflammation has been controlled by 
anti-TNF, the damage to local tissue20-22 and the changes in neuroplasticity and central 
sensitization still persist.
71
Anti-TNF-α in CRPS
Following this thought, it makes sense to start treatment of CRPS as early as possible 
to minimize the complications of this devastating disease. However, this might explain 
the restricted effect of anti-TNF on (most) of the outcome parameters.
Another limitation is the inclusion of patients based on a criteria set of physical symp-
toms. It is known that CRPS can express itself in more than one extremity. In this study, 
we make use of the contra-lateral extremity as control. It is unlikely, however we cannot 
definitely exclude influence of this phenomenon. Maybe it would be more appropriate 
to include only those patients with a high concentration of inflammatory mediators 
in the involved extremity and normal values in the contra-lateral extremity, especially 
TNF-α.
Definite conclusions are difficult, on one hand due to lack of power, and on the other 
hand due to the increased level of type 2 error as a result of multiple comparison, which 
might have lead to incorrectly rejecting the null-hypothesis of no difference.
Therefore, a larger follow-up study on the effects of TNF-α antagonists on inflamma-
tion in CRPS patients is recommended. Hopefully, this contributes to a better under-
standing of the mechanism of interactions in CRPS. However, considerations should be 
made on the selection criteria for inclusion of patients; the primary outcome measure 
should be considered as well. One might well consider whether the choice for inflam-
mation was ideal.
In spite of the small study group, a promising trend was found toward an effect of in-
fliximab on the initially high TNF-α concentration in patients with neuroinflammation in 
acute CRPS. Infliximab appears to be a safe treatment for patients with regional inflam-
mation in the acute stage of CRPS. Unfortunately, because this study was terminated 
before the required number of participants for sufficient power had been reached, we 
cannot draw any definite conclusions.
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AbStRACt
There is convincing evidence that inflammation plays a pivotal role in the pathophysiol-
ogy of complex regional pain syndrome (CRPS). Besides inflammation, central sensiti-
zation is also an important phenomenon. Mast cells are known to be involved in the 
inflammatory process of CRPS and also play a role (at least partially) in the process of 
central sensitization.
In the development of a more mechanism-based treatment, influencing the activity 
of mast cells might be important in the treatment of CRPS.
We describe the rationale for using medication that counteracts the effects of mast 
cells in the treatment of CRPS.
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intRoDuCtion
Complex regional pain syndrome (CRPS) is a painful and disabling complication after 
surgery or physical trauma, but spontaneous development is also described.
A careful clinical evaluation of signs and symptoms remains the cornerstone of CRPS 
diagnosis. The general acceptance of the IASP diagnostic criteria for diagnosing CRPS 
has contributed to improved clinical communication and the ability to generalize re-
search findings.1
The estimated overall incidence rate of CRPS is 26.2 per 100,000 person-years.2 Fe-
males are affected at least three times more often than males. The upper extremity is 
affected more frequently than the lower extremity, and a fracture is the most common 
precipitating event (44%). Severe CRPS outcome is rare, but a majority of patients still 
suffer from persistent impairments two or more years post onset.3
It is reasonable to assume that different mechanisms are involved in a complex net-
work of interactions, resulting in the painful and impairing disorder of CRPS.4 There is 
evidence that inflammation is one of the mechanisms that play a role in the pathophysi-
ology of CRPS. The contribution of inflammation is also underlined by the successful 
reports from studies on treatment with immunomodulating agents, recently reviewed.5
The use of immunomodulating medication may counteract the ongoing inflamma-
tion; early use may be an important step in preventing sensitization. Therefore, such 
treatment may play an important role in recovery of the disabled hand or foot. However, 
it is unknown whether (apart from the immunomodulating medication) other drugs 
might also counteract the inflammation. Based on empirical findings on the role of mast 
cells in the pathophysiology of inflammation in CRPS6, we describe the rationale for the 
use of medication targeting mast cell activity.
PAthoPhYSiologY of CRPS
Complex regional pain syndrome often displays the classic aspects of inflammation.7 
Inflammation contributing to CRPS can arise from two sources.8 First, classic inflam-
matory mechanisms can contribute through actions of immune cells (such as lympho-
cytes and mast cells), which, after tissue trauma, secrete pro-inflammatory cytokines 
including interleukin-1β, -2,-6, and tumor necrosis factor (TNF)-α. Secondly, neurogenic 
inflammation may also occur, mediated by release of pro-inflammatory cytokines and 
neuropeptides directly from nociceptive fibers in response to various triggers. Neuro-
peptide mediators involved in neurogenic inflammation include substance P, calcitonin 
gene-related peptide, and bradykinin (which is also involved in initiating cytokine 
release).
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Over time, various studies have report the role of inflammation in the patho-
physiology of CRPS. In venous blood of patients with CRPS elevated mRNA levels of 
pro-inflammatory cytokines, TNF and IL-2 have been found, as well as a reduction of 
mRNA levels of the anti-inflammatory cytokines IL-4 and IL-10.9 However, local rather 
than systemic inflammatory responses appear to be relevant in CRPS.10 No significant 
changes in serum parameters in CRPS were found compared with control groups, 
indicating the local formation of mediators. The presence of a local inflammation was 
already suspected based on evidence found in a scintigraphic study on CRPS, which 
demonstrated vascular permeability for macromolecules.11 Technetium 99m-anti-TNF-α 
antibody scintigraphy revealed that TNF-α was only localized in the affected hand of 
patients with early CRPS.12
Increased levels of pro-inflammatory cytokines have been detected in fluid from arti-
ficially raised skin blisters in the involved extremity in comparison with the contra-lateral 
site; however, no correlation was found between levels of pro-inflammatory cytokines 
and the characteristics or duration of the disease.13-15 Using multiplex bead array assays 
to establish the involvement of cytokines in inflammatory processes revealed 10 detect-
able representative cytokines in blister fluid of CRPS patients.16 This finding suggests 
that these mediators were generated by a homogenous cell population. Because T-cells 
are apparently not involved, the most likely candidates are monocytes, macrophages 
and, possibly, fibroblasts and skin mast cells.
Mast cells are known to be involved in CRPS.6 Tryptase is a specific proteolytic enzyme 
and a good marker of the presence of mast cells. Activated mast cells synthesize and 
release tryptase. Significantly higher levels of tryptase have been demonstrated in 
the involved extremity compared with the contra-lateral extremity. A significant cor-
relation between levels of IL-6 and TNF-α in the involved extremity was observed, but 
no significant correlation was found between levels of tryptase, IL-6 and TNF-α. Also, a 
significant correlation was found between the reported pain intensity as measured on a 
visual analog scale (VAS) and tryptase levels in the involved extremity, but not between 
the VAS and IL-6 or between the VAS and TNF-α.6
Pro-inflammatory cytokines and neuropeptides are responsible for peripheral sensi-
tization leading to increased nociceptive responsiveness. Persistent or intense noxious 
input resulting from tissue damage or nerve injury triggers increased excitability of 
nociceptive neurons in the spinal cord, a phenomenon called ‘central sensitization’.8 An 
objective phenomenon which is associated with central sensitization is windup, which 
is reflected in increased excitability of spinal cord neurons. CRPS patients display signifi-
cantly greater windup to repeated stimuli.8
The anatomical proximity of mast cells to neurons in both the central nervous system 
(CNS) and peripheral nervous system, their migratory ability, and their ability to release 
potent vasoactive and inflammatory mediators, constitutes an important neuroimmune 
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axis.17 The presence of ‘cross-talk’ has been shown between mast cells and cells of the 
CNS in various neurodegenerative diseases having an inflammatory and/or autoimmune 
component. The CNS interacts with the immune system by means of its neuropeptides, 
neurohormones, and neurotransmitters; in turn, the immune system feeds back to the 
brain which subsequently induces changes both in behavior (sickness response) and 
in the immune system.18 Nerve plasticity and remodelling occur extensively during an 
inflammatory process, in that there is an increase in nervous innervation as well as mast 
cell density.
new PAthoPhYSiologY-bASeD PeRSPeCtiVeS foR PhARMACologiCAl 
inteRVention
Mast cells are bone-marrow-derived cells capable of secreting many active molecules: 
mediators stored in specific granules (such as histamine and heparin); small molecules 
produced immediately upon stimulation (such as nitric oxide); and many constitutively 
secreted, pleiotropic cytokines.19 They play an important role in innate or acquired im-
munity, in bacterial infections, and also in autoimmunity.20 A number of cytokines (e.g., 
IL-1, IL-6, TNF) are synthesized de novo and released several hours after stimulation.
Thus, because mast cells are known to be involved in inflammation in CRPS6, it can 
be assumed that controlling these cells might (in part) improve inflammation in CRPS.
Counteracting the effects of the mast cell can be achieved by the following: (1) pre-
vention the division of, or killing the cell, (2) prevention of release, or (3) use of anti-TNF/
anti-IL 6 therapy when TNF-α/IL-6 is released.
Prevention of division/killing the mast cell
This effect is achieved by means of tyrosine kinase inhibitors. They inhibit the intrinsic 
tyrosine activity of several specific proteins, including KIT.21 KIT is a transmembrane 
protein expressed on a variety of cells, including mast cells. In mast cells, KIT acts as 
a receptor for the stem cell factor. Binding of the stem cell factor on KIT is essential 
for the survival, differentiation, chemotaxis, and functional activity of mast cells. Thus, 
inhibition of KIT results in decreased mast cell population and activity.
Inhibition of the intrinsic activity of several proteins also results in reduced tumor ves-
sel growth or carcinogenesis. Examples include imatinib (Glivec), which became clini-
cally available in 1998 for the treatment of patients with chronic myeloid leukemia in 
the chronic phase resistant to interferon-α22 and sunitinib, an anticancer drug currently 
used in the palliative treatment of metastatic renal cell carcinoma and gastrointestinal 
stomal cell tumors.21 As far as we know, these two drugs have not yet been used in CRPS.
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Prevention of release from the mast cell
This effect can be achieved by means of 3 types of drugs.
The first type is glucocorticoids. Besides the fact that glucocorticoids are anti-
inflammatory via a number of mechanisms23, they also appear to affect mast cells de-
granulation.24 They could rapidly inhibit IgE-mediated exocytosis and histamine release 
of mast cells. This effect is not accomplished by direct action on secretion machines, but 
is mediated by a reduction in the [Ca(2+)](i) elevation.
The second type is the anti-histamines. Cytokine production by human mast cells can 
be modulated (to some extent) by the H1-antagonists (e.g. azelastine, loratadine, and 
cetirizine) as well as by the H2-antagonist ranitidine.25 Of the cytokines studied, TNF-α 
has been shown to be the most susceptible to inhibition by antihistamines. The exact 
mechanism of action of antihistamines on cytokine secretion from mast cells remains to 
be elucidated.
Finally, there is the cell stabilizer. Disodium cromoglycate is a cell stabilizer which 
inhibits the release of preformed and newly synthesized chemical mediators from a 
variety of cells involved in allergic and inflammatory responses. It is assumed that cro-
moglycate acts on the lipid bilayer membrane and thereby regulates the degranulation 
of mast cells by stabilizing membrane fluidity.26
Although the use of glucocorticoids in CRPS appears to have a positive effect, empiri-
cal evidence for their use is scarce.5, 27 The mechanism by which this effect is achieved is 
not yet clear. Neither cromoglycate nor antihistamines have been used in the treatment 
of CRPS.
use of anti-tnf therapy/anti-il-6
If release of cytokines does occur, it might be useful to administer drugs which affect 
these cytokines.
Anti‑TNF
* Tumor necrosis factor-α antagonists
Tumor necrosis factor alpha (TNF-α) is a cytokine which promotes the inflammatory 
response. The possible mechanisms of action of anti-TNF agents are, for example, inhibi-
tion of the inflammatory ‘cytokine cascade’ mediated by TNF, sequestration of TNF by 
binding, and complement-mediated lysis of cells expressing TNF.28
The effect of using this drug in the treatment of CRPS has been described in 2 case 
reports of 3 patients.29, 30 All 3 patients showed improvement in pain, temperature, and 
motor function.
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* Thalidomide
Thalidomide exerts a selective effect by suppressing TNF-α secretion only. It inhibits 
TNF-α production by human blood monocytes, without influencing either general 
protein synthesis or the expression of other monocyte-derived cytokines.31
In 2 case reports, thalidomide was introduced for CRPS patients with a comorbid con-
dition.32, 33 In both cases, there was a beneficial effect on CRPS. An open-label study, in 
which 42 patients were treated, has shown a “dramatic response” in 17% of the patients, 
and 14% experienced at least modest pain relief and/or showed some reduction in the 
need for concurrent medication.34 No results for the remainder of the patients have been 
reported.
Anti‑IL‑6
Interleukin (IL)-6 is a pleitropic proinflammary cytokine that is produced by multiple 
cell types. IL-6 signal transduction is mediated by membrane-bound and soluble IL-6 
receptors. Tocilizumab (TCZ) is a recombinant humanized anti-human IL-6 receptor 
monoclonal antibody. TCZ binds to both of these receptors and inhibits signalling via 
this route.35 TCZ has been approved for the treatment of rheumatoid arthritis in patients 
who have an inadequate response to one or more TNF-α inhibitors. Until now, TCZ has 
not been used in CRPS.
SuMMARY AnD ConCluSion
Woolf and Decosterd advocated a form of pain treatment based on the mechanisms 
involved in the pathogenesis of pain.36 The aim should be to identify in each patient 
which mechanisms are responsible for their pain and specifically target treatment to 
those mechanisms.
Following this recommendation, the treatment of CRPS should be based on knowl-
edge of the pathophysiological mechanisms underlying this condition.
It is assumed that several mechanisms play a role in CRPS, one of which appears to be 
inflammation. Mast cells generate pro-inflammatory cytokines which are involved in the 
inflammatory process of CRPS. Also, central sensitization is common in CRPS. In general, 
mast cells appear to be involved in the cross-talk with the CNS; this process could play a 
role in central sensitization in CRPS.
It appears appropriate to correct the baseline inflammatory status to lower disease 
activity and, thus, lower production of pro-inflammatory cytokines. Treating the inflam-
matory component of CRPS might also prevent central sensitization. Therefore, following 
the recommendations of Woolf and Decosterd, it is reasonable to tackle the mast cell.
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It is difficult to decide which of the above-mentioned strategies for modulating mast 
cell activity might be preferred. Therefore, in selecting a drug for study, it seems wise to 
take into account the safety profile, side-effects, ease of treatment, and the cost of the 
drugs associated with each of the options.
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Complex Regional Pain Syndrome (CRPS) is characterized by a continuing regional pain 
that is disproportionate in time or degree to the usual course of any known trauma or le-
sion. The pain is regional, not in a specific nerve territory or dermatome, and usually has 
a distal predominance. CRPS is also characterized by a variable progression over time.
Apart from pain, additional clinical signs include disturbed blood flow to the skin or 
abnormal sudomotor activity, motor dysfunction, and trophic changes in the affected 
extremity. Based on signs and symptoms in the individual patient, it is possible to classify 
subtypes of CRPS: 1) a relatively limited syndrome with vasomotor signs predominating, 
2) a relatively limited syndrome with mainly neuropathic pain/sensory abnormalities, 
and 3) a florid CRPS syndrome similar to ‘classic RSD’ descriptions.1
The pathophysiology of CRPS is complex and still not completely understood. Differ-
ent mechanisms are known to be involved in the pathophysiology of CRPS, including 
inflammation, hypoxia, dysregulation of the autonomic nervous system, and changes in 
the somatosensory system.2 In addition to the convincing role for inflammation, there 
are arguments to support involvement of the immune system in the pathophysiology of 
CRPS. For example, CRPS shows a beneficial response to treatment in open-label studies 
on treatment with immunomodulating medication, such as infliximab3 and immuno-
globulin.4 Furthermore, similar to other inflammatory diseases, CRPS displays a female 
predominance5 as well as an association with distinct human leukocyte antigen (HLA) 
alleles.6-8
In the work presented in this thesis, various immunological aspects in CRPS have 
been examined with the aim to achieve more insight into both the pathophysiology of 
CRPS and the potential pharmaco-therapeutic consequences of its treatment.
With regard to inflammation, aspects of both the clinical features of inflammation 
and asymmetric levels of the pro-inflammatory cytokines (TNF-α and IL-6) in CRPS have 
been explored.
It is assumed that patients with warm CRPS suffer from inflammation and that the 
asymmetric level of cytokines reflects the presence of inflammation. In cold CRPS, 
inflammation is generally assumed not to be present.2 However, some patients with 
cold CRPS patients have displayed full-blown symptoms of warm CRPS after successful 
treatment with vasodilatation therapy.9 Our study showed that three patient groups, dif-
fering in asymmetrical level of temperature (e.g. warm, cold and intermediate), showed 
no significant differences in asymmetric levels of the pro-inflammatory cytokines TNF-α 
and IL-6. This is in accordance with the idea that (a subgroup of ) patients with cold CRPS 
might still suffer from inflammation. This finding implies that we should question the 
clinical grouping of CRPS patients into cold versus warm CRPS. It might be more ap-
propriate to differentiate between patients who have inflammation and those who do 
not. This could, in turn, have therapeutic consequences, i.e. patients with underlying 
inflammation may benefit more from a therapeutic intervention which influences the 
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ongoing inflammation, rather than therapy that aims to influence the clinical aspect 
(such as vasodilators for cold CRPS). Therapy focused on influencing the clinical aspects 
could be one of the reasons why clinical trials have failed to demonstrate the efficacy of 
many commonly used interventions in CRPS.
A particular challenge of this approach is that the test commonly used to confirm the 
presence of inflammation, i.e. determining the pro-inflammatory cytokine levels in fluid 
from artificial skin blisters, is a time-consuming procedure. Until now, this has restricted 
its use to the field of research and makes it almost impossible to apply in clinical practice. 
In CRPS, the development of a simple, easy-to-use and inexpensive diagnostic method 
to demonstrate inflammation is urgently required.
Furthermore, in an individual patient, more than one mechanism can play a role in 
the pathophysiology of CRPS at the same time. Therefore, the often applied approach 
of a single-mechanism intervention, both in research and in clinical practice, will prob-
ably be disappointing. This implies that, if in the case of cold CRPS there is vasomotor 
disturbances in addition to inflammation, then the patient will probably derive more 
benefit from a multi-mechanism targeted approach. Notably, the only multi-mechanism 
therapy applied nowadays for CRPS, is spinal cord stimulation. This latter therapy has a 
positive effect on both the somatosensory system and vasomotor disturbances.10 It is 
one of the few therapies that has proven successful in CRPS.11 Future research needs to 
focus on a multi-mechanism treatment regime for application in CRPS.
Based on an animal model of CRPS, Coderre and colleagues suggested that the inflam-
mation in CRPS is a continuum, in which the vasomotor disturbance is a consequence 
of the inflammation.12 This is another interesting idea, because the focus is no longer on 
the different subtypes of CRPS but rather on the continuum of inflammation.
Autoimmunity has been suggested as one of the underlying mechanisms in the 
pathophysiology of CRPS. We explored the potential role of systemic and/or organ-
specific autoimmunity. To do this, the prevalence of CRPS patients with a positive test 
for antinuclear antibodies (ANA) and for anti-neuronal antibodies was compared with 
the prevalence in the healthy population. The ANA prevalence was significantly higher 
in CRPS patients compared to the healthy population; however, this did not apply for 
the prevalence of the anti-neuronal antibodies. Also, the immunofluorescence pattern 
of the anti-neuronal antibodies proved to be different in CRPS patients compared to the 
healthy population. In CRPS patients, the prevalence of ANA was more similar to that 
observed in patients with an autoimmune disease such as rheumatoid arthritis (also 
referred to as an auto-inflammatory disease) than that in patients with a classic systemic 
autoimmune disease (like systemic lupus erythematosus), with a much higher observed 
prevalence.13 This is a relevant finding because it may affect the choice of treatment. For 
example, use of medication such as TNF-α antagonists is more successful in an auto-
inflammatory disease than in the classic auto-immune disease.
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In order to define CRPS as an autoimmune disease, then Witebsky’s criteria for an 
autoimmune disease should be considered.14 These criteria include: 1) demonstration 
of a specific antigen, 2) circumstantial evidence of an autoimmune or inflammatory dis-
order from clinical clues, and 3) reproduction of clinical features in recipient animals by 
passive transfer of putatively pathogenic antibodies. CRPS definitely meets the second 
criteria. There are indications that the first criterion is also met; however, this applies only 
to some patients and more research is needed to define the specific antigens involved. 
Injection of serum-IgG from a CRPS patient into groups of mice resulted in abnormal 
physical behavior and a significant reduction in rearing.15 However, because these find-
ings are not a reproduction of the clinical features, as needed for the third criterion, the 
proposal by Goebel and colleagues16 to define CRPS as a novel kind of autoimmune 
disease does not seem correct. Based on the results from our study, CRPS seems to be an 
auto-inflammatory disease.
Immunomodulating medication reduces the manifestation of inflammation by influenc-
ing the mediators of inflammation, such a cytokines, neuropeptides, eicosanoids and 
amino acids. If one assumes that inflammation plays an important role in CRPS, then one 
would expect immunomodulating medication to be effective. In the Netherlands, CRPS 
patients are treated according to the Dutch guidelines for CRPS17, i.e. for inflammatory 
signs and symptoms free-radical scavengers are advised, whereas immunomodulating 
medication is not advised. However, CRPS has shown a beneficial response to some 
immunomodulating medication.3,4 Therefore, a literature review was conducted to as-
sess the empirical evidence for the efficacy of administering the most commonly used 
immunomodulating medication (i.e. glucocorticoids, TNF-α antagonists, thalidomide, 
bisphosphonates and immunoglobulins) in CRPS patients. Unfortunately, none of the 
studies measured (an improvement in) levels of inflammation. Furthermore, evidence 
for the use of immunomodulating medication proved to be small; the exception to this 
was the use of bisphosphonates, for which all four double-blind randomized controlled 
trials showed a significant decrease of pain.18-21 It is noteworthy that, in contrast to our 
findings, another research group concluded that there was insufficient evidence based 
on these four randomized trials.22
To test the assumption that TNF-α antagonists can reduce the manifestation of inflam-
mation in CRPS, a double-blind randomized placebo-controlled trial was conducted. 
Unfortunately, this study was terminated before the required number of patients for 
sufficient statistical power had been reached. Nevertheless, the limited data showed a 
trend towards a greater reduction of TNF-α in the intervention group compared with the 
placebo group.
Another research group presented a case series of CRPS patients in which adalim-
umab (TNF-α antagonist) was used.23 Their results suggest that TNF-α antagonists can 
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be potentially useful in some patients, but not in all. There seem to be responders and 
non-responders for this treatment in CRPS.
There are several possible reasons for this changing effect (responders vs. non-
responders). It seems appropriate to include only those patients with a high concen-
tration of TNF-α in the involved extremity compared to the contralateral side. In other 
words, inflammation must be confirmed and the use of signs and symptoms alone is 
not adequate. Further, continuing inflammation is probably responsible for central 
sensitization, which is a common feature in CRPS.24 This means that even when the 
inflammation has been controlled by medication, the central sensitization still persists. 
If central sensitization is present, it probably better to start multimodal therapy instead 
of monotherapy. In other words, different mechanisms can play a role at the same time 
and must be identified (and also be treated).
Unfortunately, there is (still) insufficient evidence to justify normal use of TNF-α 
antagonists. However, due to the growing evidence for the involvement of TNF-α in 
inflammation in CRPS, the directions for an auto-inflammatory disease, and the effect 
of TNF-α antagonists in some patients, a new randomized trial seems warranted. Future 
CRPS research on anti-inflammatory medication and, more specifically anti-TNF, needs 
to establish predictors to identify responders versus non-responders to this kind of 
therapy.
Mast cells are known to be involved in the inflammatory process of CRPS25 and also 
play a role in the process of central sensitization. Therefore, influencing the activity of 
mast cells seems to be another therapeutic option. We have examined the possibilities 
of such an approach. Further exploration of the role of mast cell in the pathophysiology 
and, consequently, new therapeutic interventions are also important items for future 
research.
In 1999, in an editorial published in Pain, Clifford Woolf advocated for a shift in pain 
medicine from a symptom-based treatment towards a mechanism-based treatment. 
This would make treatment more rationale and, hopefully, more successful.26 However, 
for CRPS much work remains to be done.
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Summary
SuMMARY
Chapter 1
The introduction describes the rationale for this thesis. The pathophysiology of CRPS is 
complex and still not completely understood. In addition to a convincing role of inflam-
mation, there are a number of other arguments why an involvement of the immune 
system has been suggested in the pathophysiology of CRPS. Therefore, some immuno-
logical aspects were further explored with the aim to achieve more insight in both the 
pathophysiology and possible treatment options in CRPS.
Chapter 2
In cold CRPS, inflammation is generally assumed not to be present. However, there are 
reports of cold CRPS patients, treated with vasodilatation therapy, who subsequently 
displayed a warm CRPS. This chapter presents the results of a retrospective analysis to 
test the hypothesis that inflammation could be ‘hidden’ behind vasomotor disturbances. 
For that purpose, we defined three types of CRPS: cold CRPS, intermediate (neither cold 
nor warm) and warm CRPS. Of these patients the difference between the level of the 
pro-inflammatory cytokines Il-6 and TNF-α in the affected extremity and that in the 
contralateral extremity was determined. The bilateral difference of the level of these cy-
tokines did not differ between patients with cold CRPS, intermediate CRPS or those with 
warm CRPS. From this finding, we conclude that inflammation may (also) be involved in 
(a subgroup of ) patients with a cold CRPS.
Chapter 3
Autoimmunity has been suggested as one of the pathophysiologic mechanisms that 
may underlie CRPS. Screening for antinuclear antibodies (ANA) is one of the diagnostic 
tests, which is usually performed if a person is suspected to have a systemic autoim-
mune disease. Anti-neuronal antibodies are auto-antibodies directed against antigens 
in the central and/or peripheral nervous system. The aim of this study was to compare 
the prevalence of these auto-antibodies in CRPS patients with that the healthy popula-
tion. We found that the prevalence of a positive ANA test is significantly higher in CRPS 
patients than in the healthy population. The prevalence of the anti-neuronal antibodies 
however did not deviate from that in the healthy population. These findings indicate 
that auto-antibodies may be involved in the pathophysiology of CRPS, at least in a 
subset of patients.
Chapter 4
Immunomodulating medication reduces the manifestation of inflammation by acting 
on mediators of inflammation. If inflammation is involved in the pathophysiology of 
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CRPS, immunomodulating medication in CRPS patients could be beneficial. This chap-
ter reviews the current empirical evidence for the efficacy of administering the most 
commonly used immunomodulating medication (i.e. glucocorticoids, tumor necrosis 
factor-α antagonists, thalidomide, bisphosphonates, and immunoglobulins).
Chapter 5
In this chapter the results of a discontinued double-blind, placebo-controlled trial of 
the anti-TNF α chimeric monoclonal antibody (infliximab) in CRPS are presented. The 
aim of the trail was to evaluate the clinical signs of regional inflammation (based on 
total impairment level sumscore: ISS) after systemic administration of infliximab. In ad-
dition, levels of mediators in the fluid of induced blisters were examined in relation to 
normalization and improvement in quality of life. This study was terminated before, for 
a sufficient statistical power, the required number of participants had been reached. 
Nevertheless, a trend was found towards a greater reduction of TNF-α in the interven-
tion group.
Chapter 6
Mast cells are known to be involved in the inflammatory process of CRPS and also to play 
a role in the process of central sensitization. In the development of a more mechanism-
based treatment of CRPS, influencing the activity of mast cells might be important. This 
chapter describes the rationale for using medication that counteracts the effect of mast 
cells in the treatment of CRPS.
Chapter 7
In the general discussion, the focus of this dissertation is explicated. The current state of 
knowledge and theory concerning the role of inflammation in CRPS is summarized. In 
addition, the findings of the trials performed are enumerated and commented. It raises 
a shift in thinking about the concept of the pathogenesis of CRPS. Nowadays, the most 
accepted idea is that we are dealing with different phenotypes of CRPS. In this way it 
is explained that there is a clinical variability in expression of the disease between pa-
tients. Here, the concept of a continuing inflammatory process with variable secondary 
consequences is presented.
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hoofdstuk 1
De pathofysiologie van CRPS is ingewikkeld en is nog niet volledig begrepen. Naast 
de overtuigende rol van inflammatie zijn er nog een aantal andere argumenten voor 
de betrokkenheid van het immuunsysteem. Een aantal immunologische aspecten zijn 
daarom verder onderzocht, met het doel meer inzicht te krijgen in zowel de pathofysio-
logie als de behandelmogelijkheden in CRPS.
hoofdstuk 2
In tegenstelling tot warme CRPS, wordt er bij koude CRPS verondersteld dat er geen 
inflammatie meer aanwezig is. Er zijn echter koude CRPS-patiënten beschreven, die 
behandeld werden met vasodilatatoren en bij wie daarna een warme CRPS ontstond. 
Dit hoofdstuk bespreekt de resultaten van een retrospectief onderzoek, waarbij de 
hypothese ‘inflammatie kan verborgen zijn door vasomotore ontregeling’ werd ge-
toetst. Hiertoe werden drie CRPS-patiëntengroepen gedefinieerd: koude, ‘intermediate’ 
(noch warm, noch koud) en warme CRPS. Van deze patiënten waren de waarden van 
de pro-inflammatoire cytokines IL-6 en TNF-α van de aangedane en de contralaterale 
zijde gemeten. Het verschil in de waarden van deze cytokines tussen de aangedane 
en de contralaterale zijde bleek niet significant te verschillen tussen de groepen. Deze 
bevinding laat zien dat er bij (een subgroep) van koude CRPS-patiënten nog sprake kan 
zijn van inflammatie.
hoofdstuk 3
Auto-immuniteit is een van de mechanismen, die ten grondslag zou kunnen liggen 
aan de pathofysiologie van CRPS. Als bij een patiënt de verdenking bestaat op een 
systemische auto-immuun ziekte, wordt deze getest op de aanwezigheid van anti-
nucleaire antistoffen (ANA). Anti-neuronale antistoffen zijn auto-antistoffen gericht 
tegen antigenen van het centrale en/of perifere zenuwstelsel. Het doel van de in dit 
hoofdstuk beschreven studie was om de prevalentie van deze auto-antistoffen in CRPS-
patiënten te vergelijken met die van de gezonde populatie. De prevalentie van ANA 
bleek significant hoger te zijn in CRPS-patiënten vergeleken met de gezonde populatie; 
voor de anti-neuronale antistoffen gold dit echter niet. Deze bevinding geeft aan dat 
auto-antistoffen waarschijnlijk betrokken zijn bij de pathofysiologie van CRPS, in ieder 
geval bij een gedeelte van de patiënten.
hoofdstuk 4
Immuunmodulerende medicijnen verminderen de inflammatie door beïnvloeding van 
de (bij de ontsteking) betrokken mediatoren. Indien inflammatie inderdaad betrokken 
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is bij de pathofysiologie van CRPS, dan zouden deze medicijnen een gunstig effect 
kunnen hebben bij CRPS-patiënten. In dit hoofdstuk wordt een overzicht gegeven van 
de empirische evidentie voor de effectiviteit bij CRPS van de meest gebruikte immuun-
modulerende medicijnen (te weten: glucocorticoïden,TNF-α antagonisten, thalidomide, 
bisfosfonaten en immunoglobulines).
hoofdstuk 5
Dit hoofdstuk presenteert de resultaten van een voortijdig beëindigd dubbelblind, 
placebo gecontroleerd onderzoek naar gebruik van een TNF-α antagonist (infliximab) 
bij CRPS. Het doel was om de (eventuele veranderingen in) klinische verschijnselen 
van lokale inflammatie te evalueren (door middel van de ‘impairment level sumscore’) 
na toediening van infliximab. Verder werd de normalisatie van de waarden van de 
mediatoren en de verbetering van kwaliteit van leven onderzocht. Er werd een trend 
gevonden voor een grotere daling van de TNF-α in de behandelgroep vergeleken met 
de placebo-groep.
hoofdstuk 6
Mestcellen zijn betrokken bij CRPS en spelen ook een rol bij centrale sensitisatie. Bij 
de ontwikkeling van een meer mechanisme-georiënteerde behandeling, zou de beïn-
vloeding van de mestcel dan ook belangrijk kunnen zijn. Dit hoofdstuk beschrijft de 
‘rationale’ voor het gebruik van medicijnen, die van invloed zijn op (de effecten van) 
mestcellen, bij de behandeling van CRPS.
hoofdstuk 7
In de discussie wordt de focus van dit proefschrift besproken. De huidige kennis en de 
theorie over de rol van inflammatie in CRPS wordt samengevat. Verder worden alle be-
vindingen (uit gedaan onderzoek) uit dit proefschrift becommentarieerd. Dit hoofdstuk 
brengt ook een andere dan de vigerende conceptualisatie van de pathogenese van 
CRPS ter sprake: bij CRPS gaat het om continuüm van inflammatie, waarbij de verschil-
lende vormen waarin CRPS zich kan uiten een consequentie hiervan zijn en dus niet op 
zichzelf staande fenotypes.
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